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ABSTRACT 
 
Inflammation is associated with an increased risk for colorectal cancer through mechanisms that 
are not well understood. Isothiocyanates, which are the bioactive components in broccoli and 
other cruciferous vegetables, have been shown to suppress COX-2 and IL-6 production from 
inflammation. The polyacetylene gymnasterkoreayne B (GKB) was previously shown to increase 
detoxification enzymes, but has not previously been tested for anti-cancer activity (1).  Here we 
tested 10% broccoli, 5% broccoli sprouts, GKB and a GKB-rich extract from Gymnaster 
koriensis (GE) for their ability to prevent inflammation-enhanced colon cancer, using the dextran 
sulfate sodium/ azoxymethane mouse model. GKB (500 µmol/kg diet daily), GE (providing an 
equal dose of GKB) and broccoli protected against some aspects of inflammation, including 
cyclooxygenase-2 levels in colonic mucosa. The extract and the 10% broccoli diet, but not 
purified GKB or 5% broccoli sprouts, protected against colon cancer, decreasing 
adenocarcinomas by 90%. These data suggest that the Gymnaster extract and broccoli are both 
promising anti-cancer products. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Overview 
 
Rates of colon cancer in developing nations around the world are on a steady rise (2). 
While developed nations, such as the United States, continue to have the highest rates of colon 
cancer; countries that are transitioning from undeveloped to developed are experiencing the most 
marked increase in colon cancer rates (3). According to the National Cancer Institute, the 2008 
annual incidence rate of colon cancer per 100,000 in the United States was 34.1 and 25.0 and in 
South Korea was 46.9 and 25.6 in males and females, respectively (3). Surprisingly, a recent 
study showed that the United States is the only country that has seen a decline in colon cancer 
incidence in both males and females (2).  
The association between inflammation and cancer began back in 1863 when Rudolf 
Virchow first discovered leukocytes in neoplastic tissues and determined that the cancer had 
originated in the presence of chronic inflammation (4). Since then, chronic inflammation has 
been linked to the development of many different cancers (5, 6). Ulcerative Colitis (UC) is a 
disease characterized by chronic inflammation of the colon. Patients suffering from UC for 
several years are at heightened risk of developing colon cancer due to prolonged, chronic 
inflammation. Indeed, excluding those with genetic abnormalities who sporadically develop 
colon cancer, patients with UC are at the highest risk of developing colon cancer when compared 
to other causes (7).  
The etiology of colon cancer is very strongly associated with genetic and environmental 
influences (8, 9). Thus, the increase of colon cancer seen in economically transitioning nations is 
often attributed to changes in diet and lifestyle, characterized by diets low in fiber, high in meat 
protein and refined carbohydrates and an increasingly sedentary lifestyle leading to obesity (3). 
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While dietary interventions have been somewhat inconclusive, regular physical activity has been 
shown to reduce risk of developing colon cancer. Interestingly, one can improve clinical 
outcomes by becoming physically active even after diagnosis (10-12). Bioactive components of 
broccoli, particularly sulforaphane, have been implicated in their ability to ameliorate 
inflammation (13-18). Studying the impact of dietary intervention on inflammation associated 
colon cancer, it is important to elucidate what role diet may play in the disease process and 
whether dietary cancer preventive methods are possible.  
 
 
1.2 Hypotheses & Aims 
 
Inflammation pilot study 1 
Hypothesis: There will be a difference in the signs of inflammation observed in mice receiving 
3% Dextran Sulfate Sodium (DSS) in their drinking water for 5 and 7 days. The severity of 
inflammation in the 7 day model will be greater than that of the 5 day model. 
Aim 1: Establish a method to measure severity of inflammation using the Disease Activity Index 
and histopathological analysis of small intestine and colon. 
Aim 2: Determine appropriate dosage of DSS in mice so that the mouse model of acute 
inflammation in the colon can be used in future studies. 
 
Inflammation pilot study 2 
Hypothesis: Mice receiving 1% DSS in their drinking water for 5 days will experience more 
severe inflammation than mice receiving this dose for 3 days. Mice will recover from 
inflammation after a 7-9 day period of plain drinking water after DSS treatment as evaluated by 
histopathology. 
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Aim 1: Re-evaluate appropriate dose of DSS to produce acute inflammation without progressing 
to morbidity or mortality in mice. Determine whether this dose can be used in a long term 
inflammation enhanced colon cancer study.  
 
Rappini inflammation study 
Hypothesis: Mild to severe inflammation will be seen in mice receiving 1% DSS in their 
drinking water for 5 days on the standard AIN-93G diet. Colon sections of these mice will reveal 
the presence of numerous inflammatory cells, edema and shortened crypts.  
In mice receiving 1% DSS in their drinking water, plus a10% broccoli or rappini diet, 
inflammation will be ameliorated and colon sections will appear normal, with the absence of 
inflammatory cells, edema, and shortened crypts.  
Aim 1: Compare dietary broccoli and rappini for efficacy at reducing or mitigating acute 
inflammation induced by DSS in C57bl/6 mice as evaluated by histopathology.  
 
Inflammation enhanced colon cancer study 
Hypothesis: Broccoli sprouts rich in sulforaphane, broccoli powder, as well as extracts from 
Korean aster (A164-a and D FR-11) when consumed as part of the diet will provide protection 
against dextran sulfate sodium/ azoxymethane-induced colon cancer in C57bl/6 mice, reducing 
tumor promotion and progression. 
Aim 1: To test the cancer-preventive activity of one promising compound, and an extract 
containing that compound, from a Korean aster plant, as well as 10% dietary broccoli and 5% 
broccoli sprouts, in a mouse model of colon cancer.  
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Aim 2: Determine safety of long term treatment of dietary components, (broccoli and broccoli 
sprouts powder, Korean compound and fraction), by pathological observation and biochemical 
evaluation of liver and other organs following necropsy. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1. Physiology & Function of the Colon 
 The colon comprises the greatest portion of the large intestine which is approximately 1.5 
meters long including the cecum and rectum. The colon consists of four segments which are the 
ascending, transverse, descending and sigmoid colon. These segments are responsible for 
absorbing the remaining electrolytes and approximately 500-1000mL of water per day which the 
small intestine has failed to absorb. Any water that is not absorbed in the colon (~50-200mL) is 
excreted in the feces. Other functions of the colon include storage and bacterial synthesis of 
vitamins, namely vitamin K, B
12
, thiamin, and riboflavin (19).   
 Fermentation is another major function of the colon and occurs when insoluble fiber, 
resistant starches, undigested amino acids and mucus are fermented by resident bacteria, 
producing gases and short chain fatty acids (SCFAs). In return, SCFAs serve as an energy source 
to increase colonocyte cell proliferation and differentiation, increase water and electrolyte 
absorption and decrease osmolality. The microflora of the colon is thought to be comprised of 
more than 500 bacterial species, of which 75% remain uncharacterized (20). The process of 
colonic bacterial fermentation, especially how this process may be modulated by diet, has been a 
source of great interest in research and in commercial food development. Prebiotics and 
probiotics in the diet are thought to increase SCFAs and consequently lead to an increase in 
healthy resident bacteria, conferring a benefit to the host in warding off disease (21, 22). In 
addition, the bacteria deconjugate dietary components (such as isoflavones), secreted xenobiotic 
metabolites (such as acetaminophen glucuronide) and conjugates of endogenous components 
(such as estrogen conjugates) creating products available for absorption (23-25).  
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2.2    Colon Cancer 
Colon cancer is the third most common type of cancer diagnosed in the Western world. It 
is the second leading cause of cancer death in the United States and the fourth leading cause of 
cancer death in Korea (26, 27). It is estimated that there are 108,070 new cases of colon cancer in 
the United States each year (139). Incidence rates in males are higher than in females, but 
colorectal cancer is the second most common type of cancer in women while it is the third most 
common in men (28). More developed regions have higher incidences and mortality rates of 
colorectal cancer than less developed regions (Figure 1). Colon cancer is significantly more 
prevalent in African Americans when compared with Caucasian Americans suggesting a 
socioeconomic factor. Some people may have a genetic predisposition to developing colon 
cancer such as Familial Adenomatous Polyposis or Hereditary Nonpolyposis Colorectal Cancer 
(29). However, epidemiological studies have estimated that only 15% of colorectal cancer cases 
are caused by these genetic defects. Hence, the etiology of colon cancer is complex and 
multifaceted. Colon cancer has been linked to genetic predispositions, environmental triggers, 
including infectious causes, and inflammatory disease, such as Crohn’s Disease and Ulcerative 
Colitis (3, 30-33). 
A recent cohort study using a North American population revealed that compared to non-
Inflammatory Bowel Disease patients, there was an increased incidence rate of colon carcinoma 
for Ulcerative Colitis (UC) patients within similar geographical locations (34). The risk of 
developing cancer for UC patients increased with age, estimated at 7-14% greater risk after 25 
years and up to 30% after 35 years. Within the same study, the increased risk of colon carcinoma 
was also higher in males when compared to females (34).  
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Figure 1. Estimated age-standardized incidence and mortality rates for colorectal cancer.  
 
Source: (28) 
 
2.3   Inflammatory Bowel Disease: Ulcerative Colitis  
Inflammatory Bowel Disease (IBD) involves chronic inflammation of the gastrointestinal 
tract and includes two forms: Crohn’s Disease (CD) and UC. The prevalence of IBD is ~100 to 
130 cases per 100,000 and the incidence is ~4 to 10 new cases per 100,000 annually. There is no 
difference in incidence rates between males and females but some populations have a greater risk 
including the United States, United Kingdom and Scandanavian countries (35).  Onset of disease 
commonly occurs across a broad age range, from 15 to 80 (36). Many symptoms are common 
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between CD and UC, including diarrhea, food intolerances, anemia, malnutrition as well as 
extra-intestinal manifestations such as weight loss, fever, renal disease, bone abnormalities, 
hepatobiliary disease, oral ulcers and arthritis (35). UC is also characterized by blood in the 
stool. This is a clinical sign which is often used to differentiate between UC and Irritable Bowel 
Syndrome; which is a disorder featuring recurrent abdominal pain and diarrhea thought to arise 
from emotional stress. Whereas CD can also present with bloody stool and thus can be 
misdiagnosed as UC, it often has more subtle symptoms which can delay a proper diagnosis. The 
main differences between CD and UC are in where and how they affect the GI tract.  In CD any 
segment of the GI tract may be affected and inflamed areas may be separated by normal areas. In 
addition, CD is transmural and often extends to the submucosa and serosa resulting in fistula 
formation, abscesses, fibrosis, submucosal thickening and possible obstruction of the bowel. In 
contrast, the inflammation in UC is restricted to the colon and occurs in a continuous area 
without being separated by any areas of normal colon. Furthermore, UC only affects the mucosal 
layer and often results in bleeding, ulceration and edema (35, 37). Since the animal model we use 
mimics human UC, I will focus on UC instead of CD in the remainder of this literature review. 
 
Pathogenesis of UC: 
The cause of UC is not well understood but it is thought to be a result of genetic and 
environmental factors coupled with an overactive immune response (Figure 2). More specifically 
it is thought that the mucosal immune system becomes dysregulated, which can cause an 
inflammatory response from a usually harmless source to expand and persist and negatively 
affect the normal microbiota (36, 38). The disease process of IBD is broken down into three 
phases – initiation, augmentation and perpetuation. Initiation involves the environmental triggers 
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that can affect the genetically susceptible individual, augmentation involves the innate and 
adaptive immune response, and perpetuation involves the regulation of the immune response. 
The initiation and augmentation phases involve both the innate and adaptive immune response, 
while the perpetuation phase involves only adaptive immunity.  
The innate immune response in the colon involves both the epithelial barrier and the 
phagocytic cells within the lamina propria, which are the macrophages, dendritic cells (DCs), 
lymphocytes, plasma cells and neutrophils. It has been noted that patients with genetic 
abnormalities in innate immunity have a higher risk of IBD.  
The adaptive immune response is involved in immune regulation, which in the gut is 
typically immune suppression, which protects commensal microbiota from immune responses. 
The immune cells involved include T cells, B cells, DCs, macrophages and NK T cells. In 
particular, T inducible regulatory type 1 (Tr1) cells and T helper 3 (TH3) cells are implicated as 
secreting interleukin-10 (IL10) and transforming growth factor β (TGFβ) respectively, which are 
cytokines involved in strong immunosuppression. The absence of IL10 in mice leads to colitis 
characteristic of Crohn’s Disease, demonstrating its potency. The current hypothesis for IBD is 
that defective regulatory T cells, specifically Type 2 CD4+ T cells, cause the perpetual activation 
of the immune response, leading to the chronic inflammation seen in IBD (39).  
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Figure 2. Etiology of Ulcerative Colitis, Adapted illustration (39) 
 
 
 
 
Diagnosis of UC: 
 The first step in diagnosing UC is to rule out other causes of chronic diarrhea such as 
Irritable Bowel Syndrome (IBS) and other forms of colitis, such as ischemic, 
pseudomembranous, infectious colitis and Crohn’s Disease. Suspected cases of UC can be 
further investigated by examining the stool for alternative causes of diarrhea. Also laboratory 
tests such as complete blood count can check for anemia secondary to blood loss and electrolyte 
abnormalities such as hypokalemia secondary to diarrhea. Erythrocyte sedimentation rate and C - 
reactive protein may also help with diagnosis as they are often elevated in UC due to systemic 
inflammation. Colonoscopy and biopsy are the main ways of diagnosing UC and differentiating 
from CD by comparing features of the diseases, such as depth and location of inflammation. For 
Failure of normal immunoregulation  
Over/persistent stimulation 
Recruitment of nonregulated cells 
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those with established UC, the physical examination and extra-intestinal manifestations can aid 
in determining the severity of the disease and the course for treatment (36).  
Treatment of UC: 
 The two areas of treatment for the patient with UC include managing the acute symptoms 
and maintaining remission. The most common therapy is 5-aminosalicylic acid (5-ASA) which 
works to reduce the immune response by suppressing cytokines and other proinflammatory 
mediators. When patients do not respond to 5-ASA or it is contraindicated, then the next option 
is oral steroids, usually prednisone. Oral steroid usage should be limited to controlling acute 
symptoms, usually one to two weeks, because of negative side effects. If patients do not respond 
to steroids, then hospitalization involving more aggressive treatments may be required until 
symptoms subside. Other common medications for UC include antibiotics and 
immunomodulators, such as azathioprine or 6-mercaptopurine. More novel treatments include 
probiotic therapies, curcumin, and infliximab (anti-TNFα). It has also recently been shown that 
cessation of smoking can increase the risk of UC, although there is no difference in incidence 
between smokers and non-smokers. In severe cases of UC or when the patient has developed low 
grade dysplasia or cancer, then colectomy is performed in order to officially eradicate the disease 
(40). While surgery often improves the patient’s quality of life dramatically, it can also result in 
complications such as pouchitis, bowel obstruction and stricture (36, 38).  
 
Mechanism of Colitis Associated Cancer Development: 
When the chronic inflammation of UC is prolonged and intense enough, the risk of 
developing colon cancer is greatly increased. All stages of cancer development are susceptible to 
and can be driven by inflammation. Reactive oxygen and nitrogen species, released by cells 
 12 
 
within the innate immune response, can cause DNA mutations, thereby affecting the tumor 
initiation phase. During tumor promotion and progression nuclear transcription factor kappa B 
(NF-κB) within CD4+ T cells is thought to promote the release of interleukin-6 (IL6) and tumor 
necrosis factor (TNF)-α. The receptors which bind IL6 and TNF-α can activate downstream 
targets, such as the Signal Transducers and Activators of Transcription (STAT) pathways. In 
particular, the STAT3 pathway is thought to be intimately involved in the promotion of colitis 
associated colon cancer by promoting tumor proliferation and survival (41). 
Cyclooxygenase-2 (COX-2) enzyme activity and prostaglandin E2 (PGE2), a product of 
COX-2 stimulation, are also thought to play an important role in tumor promotion and 
progression. These pro-inflammatory proteins are thought to lead to increased angiogenesis and 
metastasis, abnormal immune modulation and suppression of apoptosis. Elevated expression of 
COX-2 can be seen in patients suffering from UC and in 85% of patients with colorectal cancer 
(42). 
 
2.4   Diet, Inflammation & Cancer 
The causes of cancer have been largely attributed to genetic and environmental factors, 
including lifestyle, and are generally thought of as either avoidable or unavoidable. Dietary 
habits have been considered for years in epidemiological and case controlled studies to have an 
impact on cancer development and prevention (43). However, this association between diet and 
cancer has never been as clear as the correlation between smoking and cancer. Overnutrition, 
leading to obesity, has also been associated with increasing cancer development in many animal 
studies and is also considered a risk factor for many types of cancer (44). Similarly calorie 
restriction appears to decrease risk for many cancers (45). A major focus of diet and cancer 
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research pertains to individual dietary components that may reduce or enhance cancer risk. 
Studying dietary components also gives more insight into the mechanisms involved in cancer 
development and how diet may play a role in modulating these mechanisms. Some examples of 
dietary factors that may enhance or prevent cancer are outlined in tables 1 and 2 respectively. 
 
Table 1. Dietary components that may enhance cancer risk Sources 
2-amino-1-methyl-6-
phenylimidazo[4,5-
b]pyridine  
(PhIP) 
 
Carcinogens present in red meat and processed meat are 
known to increase the risk of developing colorectal cancer. 
A small clinical trial showed that a diet high in cruciferous 
vegetables (broccoli and Brussels sprouts), can increase 
excretion of PhIP by induction of detoxification enzymes 
suggesting one mechanism by which broccoli reduces colon 
cancer risk. 
 
(46) 
Alcohol Cancer of the oral cavity, pharynx, larynx, esophagus, liver, 
colorectum and female breast are considered inversely 
related to increased alcohol consumption. The mechanism is 
unclear but may involve increased reactive oxygen species 
and/or support of the Warburg effect, which is the change in 
energy production associated with decreased NAD/NADH. 
(47) 
Beta carotene Two clinical trials have shown that beta carotene 
supplements increase the risk of lung cancer in smokers. 
Eating fruits and vegetables containing beta carotene is 
associated with cancer reduction but this has not been 
shown to be attributed to beta carotene. Furthermore, the 
dose of beta carotene which enhanced cancer risk was two 
orders of magnitude greater than normal blood beta 
carotene. 
(48) 
Natural carcinogens Aflatoxin is produced from aspergillus flavus on corn and 
other crops, including peanuts; this fungus grows 
particularly well in hot, humid climates. Aflatoxin is a cause 
of liver cancer. 
(43) 
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Table 2. Dietary components that may decrease cancer risk Sources 
Fruits and 
vegetables 
 
There is enough evidence from epidemiological studies to 
warrant a recommendation by the FDA that consuming at least 
5 servings of fruits and vegetables daily may decrease risk for 
cancer. 
(49) 
 
American 
Cancer 
Society 
Phytochemicals  Many dietary compounds possess cancer preventive properties 
including, curcumin, luteolin, resveratrol, genistein, lycopene 
and sulforaphane which act by various mechanisms. 
(50) 
 
(51) 
Antioxidants  Most plant phytochemicals are also antioxidants in vitro. 
Polyphenolic compounds have been of particular interest due to 
their antioxidant properties such as those from green tea, 
including epigallocatechin-3-gallate, and berries, including 
proanthocyanidins.  
(50) 
Calcium Controlled clinical trials have shown a moderate reduction of 
colorectal cancer with intake of calcium supplements, but the 
evidence is inconclusive. 
(52) 
Folate There is conflicting evidence which indicates that folate can be 
protective against cancer in early stages of cancer but possibly 
enhance cancer in later stages. 
(53) 
Selenium Epidemiological evidence has shown that selenium has a 
significant impact on reducing cancer risk, especially prostate 
cancer. A clinical trial in which the primary focus was skin 
cancer, found decreased prostate cancer risk with ingestion of 
selenized yeast. Protection was not repeated in the SELECT 
trial. 
(54) 
 
(55) 
Vitamin E Many studies have shown that vitamin E supplementation can 
protect against prostate cancer. Some have suggested that 
vitamin E supplements be used in prevention of prostate cancer 
in men at high risk. Protection was not repeated in the SELECT 
trial. 
(56) 
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2.5   Animal Model Selection 
 We chose to use the Dextran Sulfate Sodium (DSS) method as an IBD model because it 
can be given in the water ad libitum, has a low rate of mortality and most importantly it mimics 
human UC in that it only affects the colon (57). Since IBD is a chronic condition we chose the 
C57bl/6 mouse because it was recently shown that DSS administration (5 day regimen of 1% 
DSS in drinking water) creates a chronic state of inflammation in this strain as opposed to an 
acute injury from which the mouse can recover (58). We ultimately chose a dosing regimen of 
1% DSS in drinking water for 7 days based on a pilot study we performed (See methods, Chapter 
3 – Pilot 2). Further validation of the DSS model was shown in a study using C57bl/6 mice in 
which they were given common human IBD drug therapies which reduced local cytokine levels 
and improved disease symptoms and histology, proving that this model truly reflects the human 
disease (59).  
Our inflammation-driven cancer model adapted from Suzuki, using one dose of 
azoxymethane (10 mg/kg mouse i.p. injection) followed by a one week rest and then a one week 
treatment of 1% DSS was chosen because it reflects how human chronic IBD can lead to colon 
cancer. In this model the C57bl/6 mouse was shown to have an incidence of colonic 
adenocarcinomas of 50% with a multiplicity of 1.0 + 1.2 (60).  
 
2.6   Cruciferous Vegetables and Cancer 
Epidemiological evidence and case control studies suggest that there is an inverse 
relationship between increased cruciferous vegetable intake and different types of cancer, 
including lymphoma (61), lung (62, 63), colorectal (64, 65), prostate (66), breast (67), and 
gastric cancer (68). Cumulatively, these studies suggest that eating 3-5 servings of broccoli a 
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week can reduce the risk of developing various forms of cancer (13). Epidemiological research 
has also identified the important role of genetic interactions in the diet-cancer relationship. In 
individuals possessing low glutathione-S-transferees activity, a diet high in cruciferous 
vegetables has been shown to significantly reduce the risk of developing colorectal cancer. These 
individuals have both GSTM1 and T1 null genotypes, indicating that ITC compounds are not 
metabolized and excreted efficiently and remain in the body providing protection against cancer 
(64).  However, this research has been contradicted in several other studies which show that 
GSTM1 positive individuals are better protected against cancer when consuming a diet high in 
crucifers (69). 
Clinical studies – Clinical studies have investigated the safety and efficacy of reducing 
cancer risk using cruciferous vegetables, including broccoli and broccoli bioactive components. 
Sulforaphane, which occurs as the glycoside glucoraphanin within broccoli, has been studied 
extensively due to its multiple anticancer properties. Only one small clinical trial (n=28) has 
investigated the effect of broccoli on colon cancer using induction of Glutathione-S-Transferase 
(GST) as a measure of efficacy. While the dose of broccoli had no significant effect on GST 
induction over the control, it was shown that GST induction in blood lymphocytes had a 
significant correlation (rs = 0.71) with that in colon mucosa (70). Induction of phase II 
detoxification enzymes, NAD(P)H:quinone oxidoreductase
 
 and heme oxygenase-1, was 
observed in mammary tissue after a single treatment of 200 µmol sulforaphane (SF). This study 
confirmed that SF does distribute to and can be measured in breast epithelial tissue (71). In a 
second study, 68 grams of broccoli sprouts were able to significantly inhibit histone deacetylase 
(HDAC) activity in human peripheral blood mononuclear cells. Inhibition of HDAC activity is 
thought to be an anticancer mechanism because HDAC is known to be greatly increased in 
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several forms of cancer (72). Another study observed the effects of broccoli on male smokers 
and non-smokers with a 200g dose of broccoli given for 10 days. While HDAC activity was not 
found to change, DNA damage measured as DNA strand breaks in lymphocytes was 
significantly decreased with broccoli treatment (73). Another study examined the safety of 
consuming broccoli sprouts extracts containing 25 or 100µmol glucosinolates or 15µmol 
isothiocyanates. After administration for 7 days (21 doses), no adverse effects were found during 
analysis of blood or urine (74).  In a study looking at bacterial communities in the colon, a 14 
day diet rich in cruciferous vegetables was able to change the bacterial composition of each 
participant when compared to the control diet lacking in fruits and vegetables. However, each 
individual responded uniquely to the high cruciferous vegetable diet, which may help illuminate 
individual exposure to isothiocyantes after gut fermentation and help predict cancer risk (75).  
Animal studies – Studies conducted in animals provide a more profound understanding of 
the mechanisms involved in the cancer protective effects of cruciferous vegetables and their 
bioactive components. Apc
min
 mice have a genetic mutation which causes them to develop many 
intestinal tumors at an early age. These mice were used to investigate the effects of SF on 
intestinal tumor development. Long-term treatment of mice with SF increased levels of 
acetylated histones in the colon and suppressed tumor multiplicity (76). Another long-term SF 
feeding study using Apc
min 
mice resulted in significantly fewer polyps in the small intestine, with 
increased apoptosis and decreased proliferation indices. Treatment with SF also significantly 
decreased the expression of pro-survival signalling pathways, including phosphorylated c-Jun N-
terminal kinase, phosphorylated extracellular signal-regulated kinases and phosphorylated-Akt, 
when compared to Apc
min
 mice without SF treatment (77).  Cancer in multiple other organs has 
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also been diminished by feeding broccoli (78, 79) or administering sulforaphane (80, 81) as 
demonstrated in various animal models.  
 
2.7   Anti-Cancer Effects of Glucosinolates and Hydrolysis Products 
Cruciferous vegetables are lauded for their health promoting properties. Some common 
vegetables of this variety include broccoli, Brussels sprouts, kale, collard greens, cauliflower, 
cabbage and watercress. The secondary metabolites within these plants exist as a result of the 
plants’ natural defense system. One such group of secondary metabolites known as 
glucosinolates (GS) consist of a β-D-thioglucose group, a sulfonated oxime group, and a variable 
side chain. There are over 120 glucosinolates already identified in various crucifers (82). 
Glucosinolates are converted to bioactive isothiocyanates (ITC) in the presence of water and 
myrosinase, an endogenous enzyme within the plant. Once the plant matrix has been disrupted 
by chewing or crushing and mixed with saliva or water, myrosinase is released from the plant 
tissue and able to break down GS into ITC. (See table 2.2). In the absence of myrosinase, GS can 
be broken down less efficiently in the colon by resident microbiota (83, 84). Nitriles, 
epithionitriles, thiocyanates or oxazolidine-2-thiones are formed depending on the presence of 
myrosinase-associated proteins, such as epithiospecifier protein. These nitriles can also be 
formed at low pH and in the presence of Fe
++
 ions in vitro; however nitriles are typically not 
bioactive compounds. After absorption, isothiocyanates, such as sulforaphane, are conjugated 
with glutathione via the mercapturic acid pathway and excreted as N-acetylcysteine conjugates 
(85).  
The major glucosinolate groups that exist in brassica vegetables are indole, aliphatic and 
aromatic. Aliphatic GS in crucifers mainly include glucoraphanin, glucoiberin, sinigrin, and 
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progoitrin; indole GS include glucobrassicin, neoglucobrassicin, methoxy-glucobrassicin, and 4-
hydroxy-glucobrassicin. The most studied isothiocyanate is sulforaphane (1-isothiocyanato-4-
methylsulphinylbutane) which is derived from glucoraphanin (Figure 3) and thought to act as an 
antioxidant, anticancer, antimicrobial and anti-inflammatory compound when ingested (14).   
 
 
Figure 3. Conversion of the glucosinolate glucoraphanin to the isothiocyanate sulforaphane 
in the presence of myrosinase and water. 
 
 
 
 
Antioxidant activity of sulforaphane from broccoli:  
Broccoli is a good source of many nutrients, including vitamin C and E, and phytochemicals, 
particularly isothiocyanates, which give it many health promoting properties. Broccoli also has 
antioxidant properties which can be attributed in part to its polyphenolic content, including 
quercetin and kaempferol (86). Vitamins C, E, and beta carotene also play a part in antioxidant 
properties (87). Long-term, isothiocyanates can upregulate a number of antioxidant enzymes. 
Sulforaphane can act indirectly as an antioxidant by increasing the levels of tissue glutathione 
and thioredoxin reductase which can help remove reactive oxygen species (88, 89). 
 
Anticancer activity of sulforaphane from broccoli: 
Broccoli contains multiple compounds which may provide protection against cancer in ways 
other than antioxidant capacity, including indole and aliphatic isothiocyanates. Sulforaphane 
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(SF), an aliphatic isothiocyanate, has the potential to work by various mechanisms to prevent the 
initiation and thwart the progression of cancer (Figure 4). One of the earliest discoveries, in the 
1980s, was that SF could upregulate detoxification enzymes in the liver, including the phase II 
enzyme glutathione-S-transferase (90), and then in 1992 quinone reductase was shown to be 
upregulated (91). Phase II enzyme induction via SF-dependent ARE-mediated transcription is 
thought to help clear carcinogens from the body and decrease the insult caused by ROS, thus 
preventing cancer initiation (13, 83).  
Detoxification of carcinogens by enzyme induction is only one of the multiple mechanisms 
by which SF has been shown to act. Sulforaphane is also involved in apoptosis, which is the 
elimination of damaged and unnecessary cells (14, 92) 
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Figure 4. Sulforaphane acts at multiple sites in cancer prevention depending on the stage 
and location of cancer. 
 
 
 
 
 
 
 
 
Detoxifcation enzyme modulation: SF inhibits phase I detoxification 
enzymes, such as cytochrome P450 1A1, and enhances phase II 
detoxification enzymes, such as quinone reductase. However, some phase I 
enzymes, such as CYP4A10 can be increased as a protective 
mechanism.(13, 82,92) 
 
Angiogenesis: SF has been shown to inhibit angiogenesis in vitro by 
reducing capillary –like tube formation and cell migration. These changes 
were shown to be attributed to angiogenesis growth factors, such as 
vascular endothelial growth factor (VEGF) and VEGF receptors, as well as 
c-myc and matrix metalloproteinase-2. In vivo studies have also shown 
that SF can inhibit VEGF.(93)  
 
Cell Cycle Arrest: SF can modulate the phosphorylation of cyclin 
dependent kinases (CDK), cyclins and CDK inhibitors possibly through the 
mitogen-activated protein kinase signaling pathway and thereby arrest cell 
cycle progression. Different phases of the cell cycle are susceptible to SF, 
including G1 and G2/M. It is thought that the cell cycle inhibitor protein 
p21 plays a role in SF mediated cell cycle arrest.(92, 94) 
 
Apoptosis: SF inhibits cancer by induction of apoptosis, by increasing 
poly (ADP-ribose) polymerase cleavage and increasing pro-apoptotic Bax 
proteins and decreasing anti-apoptotic Bcl proteins. Also, by conjugation 
with glutathione during its metabolism, SF increases reactive oxygen 
species thereby disrupting the mitochondrial membrane and causing 
apoptosis.(13, 82, 94) 
 
Cell proliferation: By inhibiting the nuclear factor kappa B transcription 
factor or through the Nrf2 pathway by disruption of AP-1 binding, SF can 
inhibit cell proliferation reducing the progression of cancer.(13, 82) 
 
Histone deacetylase (HDAC) inhibition: HDAC, an enzyme which 
removes acetyl groups from N-acetyl lysine amino acids on histones, is 
thought to be involved in the transcriptional regulation of cell 
differentiation, apoptosis and cell cycle progression and is increased in 
cancer development. SF has been shown to inhibit HDAC activity in 
prostate and colon cancer cell lines as well as in APCmin mice.(76, 82) 
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2.8     Anti-inflammatory properties of sulforaphane from broccoli 
A known risk factor for developing colon cancer is chronic inflammation. As mentioned 
previously, Inflammatory Bowel Disease can often lead to colorectal cancer, the risk ranging 
from 0.9 to 8.8-fold in patients with Ulcerative Colitis (95). Chronic inflammation leads to the 
up-regulation of pro-inflammatory enzymes, such as COX-2, which can lead to the increased 
expression of prostaglandins. Elevated levels of prostaglandins have been associated with 
decreased apoptosis, and increased proliferation and metastasis of cancer cells (92). Many 
studies have observed that anti-inflammatory drugs and some dietary compounds are capable of 
reducing inflammation in human UC, as well as in animal models of Colitis-Associated Colon 
cancer (33, 77, 96-99).  
Sulforaphane may also impact colon carcinogenesis through inhibition of inflammation 
by affecting detoxification enzymes and by impacting genes in the inflammation pathway.  
Recent studies in Apc
min
 mice have revealed that sulforaphane can reduce inflammation and thus 
reduce colon tumorigenesis (77, 100). A potential mechanism by which sulforaphane can act as 
an anti-inflammatory is through the Nuclear Factor erythroid 2-Related Factor 2 (Nrf2) pathway, 
which regulates the antioxidant response element important in ameliorating oxidative stress. 
Since oxidative stress plays an important role in cancer development, anything that may alter the 
Nrf2 pathway is a target of interest in cancer prevention.  Sulforaphane also is known to 
inactivate the pro-inflammatory transcription factor Nuclear Factor kappa B (NF-kB), resulting 
in the reduced induction of COX-2 and inducible Nitric Oxide Synthase (iNOS) expression, as 
well as decreased TNF-α secretion (92). In another study, sulforaphane was effective at 
increasing production of two anti-inflammatory cytokines thought to reduce cancer risk, IL-2 and 
interferon-γ, in tumor-bearing Balb/c mice (101). A couple of studies have also demonstrated 
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that sulforaphane may reduce inflammation by induction of the phase II detoxification enzyme, 
NQO1 (102, 103).  
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CHAPTER 3 
INFLAMMATION PILOT STUDIES 
 
 
3.1   Introduction:  Inflammation pilot study 1 
 The purpose of this pilot study was to establish the mouse model of acute inflammation 
in the colon so that it could be used in future studies in our lab group.  Further investigations of 
how diet can impact inflammation and how the diet-inflammation interaction can impact cancer 
development have subsequently been performed. After a review of the literature we found that a 
common method of studying inflammation in rodents is to treat with Dextran Sulfate Sodium 
(DSS) dissolved in the drinking water. One research group had shown that after 5% DSS the 
C57bl/6 mice experienced inflammation that was too severe. However, they have shown that 3% 
DSS given for 5 days was able to produce less severe inflammation and mice carried out to 30 
days only had mild inflammation (58). We developed our model based on this information.  
 
3.2   Methods 
Animal Care: 
Eight to ten week old male C57BL/6 mice were purchased from Harlan Laboratories 
(Indianapolis, IN). Mice were housed individually in shoebox cages at the Institute for Genomic 
Biology animal facility at the University of Illinois (Urbana-Champaign) and maintained under 
12-hour light/dark cycles at 22˚C and 60% humidity. All animals were allowed water and AIN-
93G diet ab libitum. After a 3 day period of acclimation mice were divided into 5 groups: group 
I, 3% DSS in drinking water for 5 days; group II, 3% DSS in drinking water for 5 days and 2 
days recovery; group III, 2% DSS for 5 days; group IV, 2% DSS for 7 days; group V, control. 
All animal care followed the approved protocol by the Institutional Animal Care and Use 
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Committee and the Division of Animal Resources at the University of Illinois, Urbana-
Champaign, in accordance with NIH regulations. 
 
Reagents: 
All diet ingredients were ordered from Harlan-Teklad laboratories (Madison, WI) and 
mixed following the Harlan-Teklad standard AIN-93G recipe (Table 3).  Dextran sulfate sodium 
(M.W. 36,000-50,000kDa) was purchased from MP Biomedicals, LLC (Solon, OH).  
 
Table 3. AIN-93G standard composition 
Formula g/Kg 
Casein 200.0 
L-Cystine 3.0 
Corn Starch 397.5 
Maltodextrin 132.0 
Sucrose 100.0 
Soybean Oil 70.0 
Celluose 50.0 
Mineral Mix  35.0 
Vitamin Mix 10.0 
Choline Bitartrate 2.5 
 
Website: 
http://www.harlan.com/research_models_and_services/laboratory_animal_diets/teklad_custom_r
esearch_diets/ain_formulas.hl 
 
 
Experimental Design: 
Mice were allowed 3 days acclimation before administering DSS in drinking water. 
Three percent (w/v) DSS was dissolved in de-ionized, distilled water and given fresh daily to 
mice for 5 days (n=6) and 3 days + 2 days recovery on regular tap water (n=6). Two percent 
(w/v) DSS was given to mice for 5 days (n=3) and 5 days + 2 days water (n=3). Control mice 
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received regular drinking water without DSS throughout study (n=1). At the end of the DSS 
treatments, mice were anesthetized using ketamine/xylazine (87mg/mL and 13mg/mL 
respectively at 0.1mL/100g BW). Blood was drawn by cardiac puncture and mice were killed by 
cervical dislocation without recovery from anesthesia. Livers were immediately perfused with 
ice-cold KCl solution (1.15% w/v) and weighed. The colon was removed distal from the cecum 
to distal from the rectum, flushed with ice-cold KCl solution, measured, and the mucosa was 
scraped and collected. All samples were snap frozen in liquid nitrogen and stored at -80˚C until 
further processing. 
 
Monitoring of Overt Signs: 
Mice were monitored daily for observable changes in behavior and inflammatory signs. 
Percent weight loss, stool formation and presence of fecal blood, if observed in mice, were given 
scores on a scale developed as a disease activity index (Table 4).  Mice experiencing severe 
inflammation were monitored closely by a veterinary technician within the facility and were 
euthanized early if they did not recover. The original experimental design was to administer 3% 
DSS for 7 days. Groups were reformulated by reducing the number of days to 5 days and 3 days 
after mice on the 3% DSS regimen showed severe signs of inflammation.  After the groups were 
separated, the number of mice in the control group was reduced to one.  
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Table 4. Disease Activity Index (scoring 0-9)1 
 
Score Weight loss Stool formation Fecal bleeding 
0 None Normal pellet None 
1 1-5% Loose stool (mild) Blood in stool (mild) 
2 5-10% Loose stool (moderate) Blood in stool (moderate) 
3 >10% Watery diarrhea Gross bleeding 
 
*Normal stools = well formed pellets 
*Loose stools = pasty stool 
*Diarrhea = liquid stool 
*Mild = intermittent, Moderate = frequent 
 
1
Mice were given a score of 0-3 for each of the three categories and the sum was used to 
determine the stage of colitis as follows: 
1-4: Mild colitis (example: 1 for wt loss, 1 for stool and 0 for bleeding = score of 2) 
5-7: Moderate colitis 
8-9: Severe colitis 
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Histopathologic examinations: 
At autopsy, the colon was removed distal from the cecum to distal from the rectum and 
flushed with 1.15% potassium chloride (w/v). The length was measured and sections were cut 
from the distal and proximal colon and fixed in 10% neutral buffered formalin. After 24 hours, 
sections were washed and placed in 80% ethanol and stored at 4˚C until further processing at the 
Veterinary Diagnostic Laboratory (University of Illinois, Urbana, IL). Fixed tissues were 
embedded in paraffin and 10 micrometer cross-sections were mounted and stained with 
hematoxylin and eosin (H&E). Slides were examined using an Olympus BX51 microscope, an 
Olympus DP70 three-chip camera and an Antec EN8900 series computer for storage of images.  
 
Statistical Analysis: 
Values are means ± SEM. Data was analyzed using ANOVA; post hoc Tukey’s test for 
multiple comparisons on SAS statistical software (SAS Institute Inc., Cary, NC).  P < 0.05 was 
considered significant.  
 
3.3   Results of Pilot 1 
Mice which were given 2 to 3% DSS experienced mild to severe inflammation of the 
colon, which involved mild to severe weight loss (Figure 5 and Figure 6). Behavioral changes 
were also noticed in some mice, including lethargy and withdrawal. On day 5 of the 3% DSS 
treatment, mouse #6 was euthanized due to severe inflammation, including severely bloody and 
loose stools and >10% weight loss. Histopathology revealed that mice given 2% and 3% had 
severe inflammation of the distal and proximal colon, with no signs of recovery. Inflammation 
could be seen in H&E sections characterized by severe edema, infiltration by inflammatory cells, 
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shortened crypts and loss of goblet cells. Colon length measured at sacrifice was also not able to 
recover to match the control (Figure 7).  
 
3.4   Conclusion to Pilot 1 
Based on these observations a second pilot study was devised using lower DSS doses to 
lessen the severity of inflammation, allowing the mice to recover from the insult with a longer 
study in mind. Since 2% and 3% DSS resulted in severe inflammation revealed by colon 
pathology we decided to lower the dose to 1% DSS for 5 days. We also decided to allow the 
mice a longer period to recover from the DSS treatment in order to see whether this would 
reduce the inflammation seen by observation and histopathology and eliminate mortality of any 
mice. 
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Figure 5. Percent weight change with DSS treatment (pilot study 1)1 
 
 
1
Male, C57BL6 mice (n=6) weighing an average of 21.1 grams were provided Dextran Sulfate 
Sodium (DSS), or tap water, as their sole drinking water, as shown. Percent weight change was 
calculated from day to day during DSS treatment.  
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Figure 6. Disease Activity Index of mice during DSS treatment (pilot study 1)1 
 
 
1
Mice (male C57bl/6, n=6) were observed daily and given a colitis score based on weight loss, 
stool formation and fecal bleeding (table 3.2). Colitis scores were characterized as mild (1-4), 
moderate (5-7) or severe (8-9).  
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Figure 7. Effect of DSS on colon length of mice (pilot study 1)1 
 
 
 
1
 Mice (male C57bl/6, n=6) were killed by cervical dislocation and colon was removed distal 
from the cecum to distal from the rectum and washed with 1.15% KCl. Colon length was 
measured from the cecal end to rectum. Mean + SEM, one-way ANOVA, p < 0.05 using Fisher’s 
LSD 
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3.5   Introduction: Inflammation Pilot Study 2 
Objective: to establish the acute colitis model using DSS with a period of recovery so that 
mice will experience a mild to moderate colon inflammation that will not progress to mortality. 
The justification is to use this irritant along with the carcinogen, azoxymethane, in an 
inflammation enhanced model of colon cancer.  Animal care, reagents, monitoring of overt signs 
and histopathology used in pilot 2 were identical to those used in pilot 1.  
 
3.6   Methods 
Mice were allowed 3 days acclimation before administering DSS in drinking water. Short 
recovery: 1% (w/v) DSS was dissolved in de-ionized, distilled water and given fresh daily to 
mice for 5 days (n=4) or 3 days with 2 days recovery on regular tap water (n=4). Long recovery: 
1% (w/v) DSS was given to mice for 5 days with 7 days recovery (n=4) or 3 days with 9 days 
recovery (n=4). Control mice received regular drinking water without DSS and were killed 
immediately after acclimation on day 0 (n=4). At the end of the DSS treatments, mice were 
anesthetized using ketamine/xylazine; blood was drawn by cardiac puncture and mice were 
killed by cervical dislocation. Livers were immediately perfused with ice-cold isotonic KCl 
solution (1.15% w/v) and weighed. The colon was removed distal from the cecum to distal from 
the rectum, flushed with ice-cold KCl solution, measured, and the mucosal scraping was 
collected. All samples were snap frozen in liquid nitrogen and stored at -80˚C until further 
processing. 
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3.7   Results of Pilot 2 
Mice which were given 1% DSS experienced mild colitis which involved mild to 
moderate weight loss (Figure 8 and Figure 9). Behavioral changes did not appear as great as the 
previous pilot study and no mice were required to be euthanized before the study was terminated. 
Histopathology revealed that some mice still experienced severe inflammation of the distal and 
proximal colon when given 1% DSS for 5 days. However with the recovery period, colon 
integrity was restored in many mice and only mild inflammation was observed. All mice 
experienced a mild degree of weight loss during DSS treatment, but weight was quickly regained 
once DSS treatment was stopped and the mice were allowed to recover. Colon length measured 
at sacrifice recovered sufficiently as to match control length in those groups given a period to 
recover (Figure 10).  
 
3.8   Conclusion to pilot 2 
Mice were able to recover from the 1% dose of DSS given for 5 days. Based on these 
observations, a dose of 1% DSS was chosen for 7 days, after administering the carcinogen, 
azoxymethane. We chose 7 days to ensure that the mice were experiencing inflammation, in 
order to make the model a legitimate model of inflammation-enhanced colon cancer. 
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Figure 8. Percent weight change in DSS (pilot study 2)1 
 
 
1
Male, C57BL/6 mice were treated with DSS in their drinking water as follows; (A) short 
recovery: 1% DSS was dissolved in de-ionized, distilled water and given fresh daily to mice for 
5 days (n=4) or 3 days with 2 days recovery on regular tap water (n=4). (B) Long recovery: 1% 
DSS was given to mice for 5 days with 7 days recovery (n=4) or 3 days with 9 days recovery 
(n=4). Body weight was measured daily and % weight change calculated for each day. 
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Figure 9. Disease Activity Index of mice during DSS treatment (pilot study 2) 
 
 
 
1
 Male, C57BL/6 mice were treated with DSS in their drinking water as follows; (A) short 
recovery: 1% DSS was dissolved in de-ionized, distilled water and given fresh daily to mice for 
5 days (n=4) or 3 days with 2 days recovery on regular tap water (n=4). (B) Long recovery: 1% 
DSS was given to mice for 5 days with 7 days recovery (n=4) or 3 days with 9 days recovery 
(n=4). Daily colitis scores were characterized as mild (1-4), moderate (5-7) or severe (8-9). 
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Figure 10. Effect of DSS treatment on colon length in mice (pilot study 2) 
 
 
 
1
Male, C57BL/6 mice were treated with DSS in their drinking water as follows; (A) short 
recovery: 1% DSS was dissolved in de-ionized, distilled water and given fresh daily to mice for 
5 days (n=4) or 3 days with 2 days recovery on regular tap water (n=4). (B) Long recovery: 1% 
DSS was given to mice for 5 days with 7 days recovery (n=4) or 3 days with 9 days recovery 
(n=4). After being flushed with 1.15% KCl, colon length was measured distal from the cecum to 
distal from the rectum. Mean + SEM, one-way ANOVA, p < 0.05 using Fisher’s LSD. 
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CHAPTER 4 
RAPPINI AND INFLAMMATION STUDY 
 
4.1   Introduction 
Broccoli (Brassica oleracea L.) diets have been shown to reverse inflammation caused 
by a number of agents, including inflammation of the colon due to DSS (104). Rappini (Brassica 
rapa L.) belongs to the same plant family as broccoli (Brassicaceae). Like broccoli, it is a rich 
source of aliphatic glucosinolates. However, the major glucosinolates in rapini are gluconapin 
and glucobrassicanapin (105). The isothiocyanate that is derived from gluconapin, 3-butenyl 
isothiocyanate, has been shown to inhibit the proliferation of HT29 colorectal cancer cells by 
disrupting the cell cycle, but there is no source indicating it has anti-inflammatory effects 
(106).The purpose of this study was to compare dietary broccoli and rappini (broccoli raab) for 
efficacy at reducing or mitigating acute inflammation induced by DSS in C57bl/6 mice.  Our 
hypotheses were that mild to severe inflammation would be seen in mice receiving 1% DSS 
treatment for 7 days on the control AIN-93G diet. Colon sections of these mice would reveal the 
presence of numerous inflammatory cells, edema and shortened crypts.  In mice receiving 1% 
DSS treatment and the 10% freeze-dried broccoli or rappini diets, inflammation would be 
ameliorated and colon sections would appear normal, with the absence of inflammatory cells, 
edema, and shortened crypts. 
 
4.2   Methods 
Animal Care: 
Eight to ten week old male C57BL/6 mice were purchased from Harlan Laboratories 
(Indianapolis, IN). Mice were housed individually in shoebox cages and maintained under 12-
hour light/dark cycles at 22˚C and 60% humidity (University of Illinois, Urbana-Champaign). 
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All animals were allowed water and AIN-93G diet ab libitum.  All animal care followed the 
protocol approved by the Institutional Animal Care and Use Committee at the University of 
Illinois, Urbana-Champaign, in accordance with NIH regulations. 
 
 Reagents: 
All diet ingredients were bought from Harlan-Teklad laboratories (Madison, WI) and 
mixed following the Harlan-Teklad standard AIN93G composition (Table 3).  Broccoli was 
grown, freeze-dried and powdered at the University of Illinois, Urbana, IL. Rappini was 
provided by D'Arrigo Bros. Co., Salinas, CA and freeze-dried at the University of Illinois, 
Urbana, IL. Broccoli and Rappini (10% w/w) were added to the diet (Table 6 and Table 7, 
respectively). Dextran sulfate sodium (M.W. 36,000-50,000 kDa) was purchased from MP 
Biomedicals, LLC (Solon, OH). 
 
Experimental Design: 
Mice were allowed 4 days acclimation (AIN93G ad libitum) before starting on treatment 
diets. After 4 days on treatment diets, 1% (w/v) DSS was dissolved in de-ionized, distilled water 
and given fresh daily to mice for 7 days, as their only source of water; regular tap water was 
given to control groups. Mice were divided into 6 groups (n=6 per group) and provided with 6 
diets (table 4.1); I: Control (AIN93G), II: AIN93G+ DSS, III: 10% Broccoli diet, IV: 10% 
Broccoli diet + DSS, V: 10% Rappini diet, VI: 10% Rappini diet + DSS. Powdered diet was 
provided ad libitum and replaced fresh daily. At the end of the DSS treatments, mice were 
anesthetized using ketamine/xylazine as described in chapter 3. Blood was drawn by cardiac 
puncture and mice were killed by cervical dislocation. Livers were immediately perfused with 
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ice-cold KCl solution (1.15% w/v) and weighed. The colon was removed distal from the cecum 
to distal from the rectum, flushed with ice-cold KCl solution, the length measured, and the 
mucosa was scraped and collected. All samples were snap frozen in liquid nitrogen and stored at 
-80˚C until further processing. Monitoring of overt signs and histological methods were identical 
to the previous pilot studies.  Mice were monitored using the Disease Activity Index described in 
Chapter 3 (Table 4). 
 
 Histopathological examination: 
Severity of inflammation was determined by examination of H&E staining of colonic 
sections with the assistance of Dr. Matthew A. Wallig, Department of Veterinary Sciences 
(University of IL, Urbana, IL).  Sections were determined to be normal or classified as mild, 
moderate or severe colitis. Sections were described as normal if they had no apparent 
mucosal/submucosal edema or presence of inflammatory cells (neutrophils, macrophages, etc) 
and if there were abundant goblet cells and the crypt epithelium was intact. Sections described as 
mild colitis had mild edema, minor shortening of the crypts and presence of low numbers of 
inflammatory cells. Sections described as moderate colitis had a greater presence of 
inflammatory cells, loss of goblet cells, more extensive edema, and irregular crypt variation and 
sometimes collapsed lamina propria. There were no sections characterized as severe colitis; 
however, these sections would have appeared to have marked edema, infiltration of numerous 
inflammatory cells, profound loss of goblet cells, severely shortened crypts, mitotic figures, 
inflamed muscularis and collapsed lamina propria.  
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Statistical Analysis: 
Differences between groups were analyzed using Student’s T-test and ANOVA followed 
by post hoc Tukey’s test for multiple comparisons. P < 0.05 was considered significant. All data 
were analyzed using SAS statistical software (SAS Institute Inc., Cary, NC).   
 
4.3   Results 
Food intake in the rappini plus DSS group was lower while receiving DSS treatments, but 
recovered by day 16 when all groups had similar intake (Figure 11). Body weight within in the 
rappini groups was consistently lower throughout the study (Figure 12). Body weight did not 
differ significantly from group to group on the first day of the study. However, by the last day of 
the study the rappini plus DSS group had significantly lower body weight compared to all other 
groups; mice receiving rappini alone had significantly lower body weights compared to mice 
receiving the control diet.  By the last day of the study, all groups had gained weight compared to 
the first day, except for the rappini plus DSS group (p<0.05). Colon length was significantly 
lower in the control (AIN-93G) DSS group when compared to the all other groups (p<0.05). 
Both the rappini plus DSS and broccoli plus DSS groups were able to maintain colon length, 
whereas the plus DSS group was 14% shorter than the control group receiving no DSS. Liver 
weights did not differ between groups (p<0.05). Histopathology showed that 66% of mice in the 
control plus DSS group had mild to moderate colitis; 33% of mice in the rappini plus DSS group 
had mild to moderate colitis; and 17% of mice in the broccoli plus DSS group had mild colitis 
(Table 5). These percentages do not correlate with the Disease Activity Index scores. Two mice 
within the broccoli plus DSS group exhibited traces of edema not considered serious enough to 
classify as mild colitis.  
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4.4   Conclusion 
DSS (1%) caused mild to moderate colitis in the control group as revealed by 
histopathology. This was associated with shortening of the colon whereas dietary broccoli and 
rappini both protected against shortening of the colon from inflammation; rappini was not as 
effective at reducing the insult caused by DSS, as revealed by histopathology. Since broccoli 
seems to have a promising effect on reducing inflammation we decided to develop our 
inflammation model into a colon cancer model. Using azoxymethane, a chemical carcinogen, 
and DSS it is possible to induce colon cancer in mice that bears resemblance to that of human 
Ulcerative Colitis, with progression to colon cancer.  
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Figure 11. Food consumption in mice receiving dextran sulfate sodium for 7 days.1 
 
 
 
1
Male, C57BL/6 mice were treated as described in methods, with AIN93G for days 1-4; 
treatment diets days 5-8 and treatment diets + DSS (1%) on days 9-16. Food consumption was 
recorded from days 2-16. Each line represents a daily average per group (n=6). 
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Figure 12. Mean body weight of mice receiving diets with and without dextran sulfate 
sodium in the drinking water.1 
 
 
1
Male, C57BL/6 mice were treated as described in methods; mice received AIN93G days 1-4; 
treatment diets days 5-8 and treatment diets + DSS (1%) days 9-16. Body weight of each mouse 
was recorded daily. Each line represents a daily average per group (n=6). 
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Figure 13. Mean body weight before and after DSS treatment.1 
 
 
1
Male, C57BL/6 mice were treated as described in methods: mice received AIN93G days 1-4; 
treatment diets days 5-8 and treatment diets + DSS (1%) days 9-16. 
 
* Indicates significant difference between first day of DSS (day 7; filled bars) and last day (open 
bars). (p < 0.05) Data are means ± standard error. T-tests were performed separately to determine 
differences between control, control/dss, broc, broc/dss, rapini and rapini/dss. 
 
Different letters indicate differences between DSS and no DSS within a dietary treatment group. 
Body weight is reported for day 0 and day 16 of study. Differences were found in all groups (p < 
0.05) excluding the rappini/DSS group, which was not different from the beginning to the end of 
the study. 
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Figure 14. Effect of diet on DSS-induced decrease in colon length1  
 
 
 
1
Male, C57BL/6 mice were treated as described in methods: mice received AIN93G days 1-4; 
treatment diets days 5-8 and treatment diets + DSS (1%) days 9-16. Colon was removed and 
flushed with 1.15% KCl and measured distal from the cecal to distal from the rectum. 
 
* Indicates a significant difference in colon length between groups. Data are mean ± standard 
error. Significant differences were determined by student’s t-test (p < 0.05) 
 
 
 
 
 
 
 
 47 
 
 
Figure 15. Effect of DSS and diet on liver weight1 
 
 
 
 
 
1
Male, C57BL/6 mice were treated as described in methods: mice received AIN93G days 1-4; 
treatment diets days 5-8 and treatment diets + DSS (1%) days 9-16. Livers were perfused with 
1.15% KCl, removed, patted dry and then weighed. Different letters indicate significant 
differences. Data are mean ± standard error. All groups were found to be not different, using 
Tukey’s test for multiple comparisons (p < 0.05). 
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Table 5. Level of colitis in DSS treated mice1 
 
Treatment Group Normal Mild 
edema 
Mild colitis Moderate 
colitis 
Severe 
colitis 
% mice 
with colitis 
AIN93G + DSS 2  3 1  66% 
Broccoli + DSS 3 2 1   17% 
Rappini + DSS 2 2  2  33% 
 
1
Male, C57BL/6 mice were treated as described in methods: mice received AIN93G days 1-4; 
treatment diets days 5-8 and treatment diets + DSS (1%) days 9-16. Severity of colitis was 
determined by histopathology.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 49 
 
Table 6.  Broccoli diet composition 
Formula (1 Kg diet) AIN-93G (g/Kg) 10% Broccoli (g/Kg) 
Broccoli -- 100 
Casein 200.0 173.64 
Celluose 50.0 25.70 
Corn Starch 397.486 375.63 
Maltodextrin 132.0 122.96 
Sucrose 100.0 93.15 
L-Cystine 3.0 3.0 
Mineral Mix  35.0 26.87 
Vitamin Mix 10.0 10.0 
Choline Bitartrate 2.5 2.5 
Soybean Oil 70 66.54 
 
Broccoli, raw (source: USDA website) 
Component Value/100g 100g (dry wt=10.7g) 
Water 89.3  
Energy 34 kcal  
Protein 2.82 26.36 
Total fat .37 3.46 
Ash (total mineral) .87 8.13 
Carbohydrate (+fiber) 6.64 62.06 
Fiber (total dietary) 2.6 24.3 
Sugars (total) 1.7 15.89 
 
Adjusted AIN-93G diet as follows: 
Subtract protein from casein 
Subtract total lipid from soybean oil 
Subtract ash from mineral mix 
Subtract starch portion of carbohydrate from corn starch 
Subtract dietary fiber from cellulose 
Subtract ratio of sugar from maltodextrin and sucrose (calculated below) 
Starch portion = total carb – total fiber – total sugar 
Broccoli starch potion = 62.06 – 24.3 – 15.89 = 21.87 
Maltodextrin               132 9.04 (=15.89*132/232) 
Sucrose    100 6.85 (=15.89*100/232) 
Total sugar (broccoli)  232 15.89 
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Table 7.  Rappini diet composition 
Formula (1 Kg diet) AIN-93G (g/Kg) 10% Rappini (g/Kg) 
Rappini -- 100.00 
Casein 200.0 157.45 
Celluose 50.0 13.76 
Corn Starch 397.486 400.58 
Maltodextrin 132.0 129.1 
Sucrose 100.0 97.8 
L-Cystine 3.0 3.0 
Mineral Mix  35.0 22.52 
Vitamin Mix 10.0 10.0 
Choline Bitartrate 2.5 2.5 
Soybean Oil 70 63.42 
 
Rappini (broccoli raab), raw (source: USDA website) 
Component Value/100g 100g (dry wt=7.45g) 
Water 92.55  
Energy 22 kcal  
Protein 3.17 42.55 
Total fat .49 6.58 
Ash (total mineral) .93 12.48 
Carbohydrate (+fiber) 2.85 38.26 
Fiber (total dietary) 2.7 36.24 
Sugars (total) .38 5.10 
 
Adjusted AIN-93G diet as follows: 
Subtract protein from casein 
Subtract total lipid from soybean oil 
Subtract ash from mineral mix 
Subtract starch portion of carbohydrate from corn starch 
Subtract dietary fiber from cellulose 
Subtract ratio of sugar from maltodextrin and sucrose (calculated below) 
Starch portion = total carb – total fiber – total sugar 
Rappini starch potion = 38.26 – 36.24 – 5.10 = -3.08 
Maltodextrin               132 2.90 (=5.10*132/232) 
Sucrose    100 2.20 (=5.10*100/232) 
Total sugar (rappini)  232 5.10 
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CHAPTER 5 
INFLAMMATION ENHANCED COLON CANCER STUDY 
 
5.1   Introduction 
Colorectal cancer is the second leading cause of death from cancer worldwide. 
Inflammatory Bowel Disease (IBD), which includes Ulcerative Colitis, increases the risk for 
developing colon cancer (107). Dietary prevention in the form of cruciferous vegetables exhibits 
an inhibitory effect on cancer development (108). Sulforaphane, which is the metabolic product 
of glucoraphanin, is an isothiocyanate present in broccoli. Sulforaphane has been shown to 
possess anti-carcinogenic and anti-inflammatory properties in animal models (13, 17). The 
purpose of this study was to determine the mechanisms by which sulforaphane and other 
components of broccoli provide protective effects against inflammation-induced cancer. These 
data are expected to enhance our capability to translate this knowledge to improving the health of 
people suffering from IBD or those at increased risk for colon cancer. 
Similarly, the incidence of colon cancer in Korea is steadily on the rise (109). At the 
Korea Institute of Science and Technology (KIST), dietary compounds are being studied for the 
prevention of cancer. There are many plants that are unique to the mountains of Korea that could 
contain promising anti-cancer components, slowing or abolishing this increasing rate of colon 
cancer. In particular, one compound, Gymnasterkoreayne B (GKB), isolated from the extract of 
the indigenous Korean plant, Gymnaster koraiensis, has shown potential therapeutic efficacy, 
including upregulation of phase II detoxification enzymes when rats were fed this component in 
their diet for five days. The phase II enzymes are known to detoxify many carcinogens resulting 
in cancer prevention. Providing natural plant components such as GKB via the diet or through 
pharmaceutical intervention may be a way to reverse the trend of increasing colorectal cancer 
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incidence in South Korea by enhancing the natural physiological ways by which the body 
protects itself from carcinogens or promoters of carcinogenesis.  Before such a product can be 
evaluated in humans, it is necessary to evaluate colon cancer prevention in rodents. This study 
evaluated colon cancer in the presence of an ethanol extract and an isolated component (GKB) 
from Gymnaster koraiensis gathered in Daegwallyeong, Korea.  
 
5.2   Methods 
Reagents: 
All diet ingredients were bought from Harlan-Teklad laboratories (Madison, WI) and 
mixed following the Harlan-Teklad standard AIN93G protocol (Table 3). Dextran sulfate sodium 
(M.W. 36,000-50,000 kDa) was purchased from MP Biomedicals, LLC (Solon, OH).  
Azoxymethane was purchased from Sigma-Aldrich (St. Louis, MO) and stored at -20ºC until 
use. Goldenrod animal lancets were purchased from MEDIpoint Inc. (Mineola, NY). Isoflurane 
was purchased from The Department of Veterinary Medicine (University of Illinois). 
Proliferating Cell Nuclear Antigen (PCNA) antibodies and Cyclooxygenase 2 (COX-2) 
antibodies for immunohistochemistry were purchased from Abcam (Cambridge, MA). Serum 
collected at the end of the study was used to measure interleukin-6 concentrations by ELISA 
(BD Biosciences; San Jose, CA). Benzylisothiocyanate was purchased from LKT Laboratories 
Inc. St. Paul, MN. 
 
Processing of dietary components: 
Approximately fifty pounds (6 cases-14 bunches/case) of Ocean Mist broccoli heads 
(Castroville, CA) were purchased from Meijer grocery store in Urbana, IL. Broccoli was stored 
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at 4˚C while being processed on the same day of purchase. Broccoli stems were discarded, 
retaining about 2 inches of broccoli floret, measured from the top of the crown. The florets were 
snap-frozen using liquid nitrogen and immediately stored in plastic gallon bags at -80˚C. Frozen 
broccoli florets were then freeze-dried using the VirTis General Purpose Freeze Dryer, model 
24DX24 (Gardiner, NY) located in the Edgar R. Madigan Laboratory at the University of 
Illinois, Urbana, IL. Freeze-dried broccoli was finely ground into a powder and stored at -20˚C 
until use.  Air dried broccoli sprouts were provided by Caudill Seed Company (Louisville, KY) 
and stored at room temperature until use.  An extract, which is a fraction from the Korean aster 
plant, Gymnaster koraiensis, and the isolated compound Gymasterkoreayne B, were provided by 
KIST (Gangneung, Republic of Korea) and stored at 4˚C until use.  
  
Animal Care & Diets: 
98 Male, C57BL/6 mice (6-8 weeks old) were purchased from Harlan Laboratories 
(Indianapolis, IN). Mice were housed individually in shoebox cages at the Institute for Genomic 
Biology animal facility and maintained under 12-hour light/dark cycles at 22˚C and 60% 
humidity (University of Illinois, Urbana-Champaign). All mice were allowed water and a 
powdered, semi-purified (AIN-93G) diet ab libitum. Mice were acclimated to the AIN-93G diet 
for 3 days (day -14 to day -12) and on diet containing the various treatments (Table 8) for 12 
days (days -11 to -1) prior to administering carcinogen (AOM/DSS).  They were randomly 
assigned to one of fourteen groups the first seven groups received AIN93G diet containing 
treatments as shown in table 5.1.  The second seven groups received similar diets/treatments to 
the first group.  However, they also received ip injection of azoxymethane (10 mg/kg) on day 0 
and DSS (1%) in the drinking water on days 7-13 (Figure 16). Because of the significant amount 
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of fiber added as broccoli or broccoli sprouts, the AIN93G diets containing these were modified 
to balance for fiber (Table 6 and Table 16 for broccoli and broccoli sprouts respectively). Korean 
plant materials were added to the soybean oil within the diet at 250 and 500µmol/kg of the diet 
(Table 15). 
 
Experimental Design: 
On day 0, after the acclimation period, mice were randomly assigned to the groups shown 
in table 5.1. Groups 1-7 received tap water without DSS throughout the study (n=7 per group). 
Serum was collected at baseline (day 0) and twice during the study (days 35 and 70); Urine was 
collected on days 0 and 14 (at the completion of DSS treatment). Urine was collected by placing 
a mouse in a small box which allowed for air passage and contained a 96 well plate. Mice were 
frequently monitored and urine was collected over a 2 hour period from the plate. Blood was 
collected from mice by mandibular puncture using Goldenrod lancets after brief exposure to 
isoflurane, and allowed to clot overnight at 4ºC to collect serum. At day 105 (week 15 after 
AOM injection), mice were anesthetized using ketamine:xylazine (87mg/ml:13mg/ml 
respectively; 0.1mL/100g BW). Blood was collected by cardiac puncture and mice were killed 
by cervical dislocation. Livers were immediately perfused with ice-cold isotonic KCl solution 
(1.15% w/v) and weighed. The colon was removed distal from the cecum to distal from the anus, 
flushed with ice-cold 1.15% KCl, the length recorded, and the entire colon observed 
microscopically for visible lesions. Lesions were measured and placed in 10% formalin for 24 
hours and stored in 80% ethanol at 4ºC until histopathological analysis. The mucosa remaining 
was scraped from the colon and stored in liquid nitrogen. Blood, colonic mucosa, and liver 
samples were snap frozen in liquid nitrogen and stored at -80˚C until further processing. 
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 Monitoring of mouse health: 
A Disease Activity Index (DAI) scoring system adapted from (58) was used to monitor 
changes in mouse health throughout the study (Table 4). Mice were monitored daily for changes 
in weight or health and a medical case record was started for any animal exhibiting changes. 
Mice placed on medical cases were observed daily for their individual symptoms (Table 9). 
Inflammatory scores were recorded and included percent weight loss, stool formation and 
presence of fecal blood.  Mice experiencing severe inflammation were monitored by a veterinary 
technician within the facility and were euthanized early if they did not recover. 
 
 Histopathology:  
Sections of colon and small intestine were fixed in 10% formalin for 24 hours. Sections 
were cut, washed and placed in 80% ethanol and stored at 4˚C until further processing at the 
Veterinary Diagnostic Laboratory (Urbana, IL). Fixed tissues were embedded in paraffin and 10 
micrometer cross-sections were mounted and stained with hematoxylin and eosin. Slides were 
examined using an Olympus BX51 microscope, an Olympus DP70 three-chip camera and an 
Antec EN8900 series computer for storage of images. Tumors were characterized as malignant 
or benign by a trained pathologist, Matthew A. Wallig in the Department of Veterinary Medicine 
(University of IL, Urbana, IL).  
 
 Immunohistochemistry:  
Colon sections were allowed to incubate for 1 hour in antibodies for Proliferating Cell 
Nuclear Antigen (PCNA) or Cyclooxygenase 2 (COX-2). Data were reported as percent 
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positively-stained nuclei. PCNA-IHC is a standard method used to measure cell proliferation 
within lesions (110), while staining for COX-2 is a measure of the severity of inflammation 
(111). Tumor fields were evaluated for hyperplasia, adenomas and adenocarcinomas. Normal 
fields evaluated included both distal and proximal sections from colons of carcinogen-treated 
mice. Normal fields within colons of carcinogen-treated mice were called such if they did not 
display adenomas, adenocarcinomas or hyperplasia. At least 500 cells were counted within each 
tumor field and at least 300 within each normal field.  
 
PCNA-labeling index (%)  = ____PCNA positive-stained nuclei____
(PCNA positive + PCNA negative nuclei)
x 100
 
 
COX2-labeling index (%)  = ____COX2 positive-stained nuclei____
(COX2 positive + COX2 negative nuclei)
x 100
 
Phase I and II Detoxification Enzyme Activity 
Activity of the hepatic phase I enzyme CYP1A was measured in the microsomal fraction as 
ethoxyresorufin O-deethylase (EROD) activity using the method of Paolini (112). The activity of 
the phase II enzyme NAD(P)H-quinone oxidoreductase 1 (NQO1) was measured in the cytosolic 
fraction according to the method of Prochaska and Santamaria (113). Methods for both 
detoxification enzyme measurements were modified slightly as previously reported (114, 115). 
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 Analysis of sulforaphane within broccoli and broccoli sprouts: 
For hydrolysis and SF analysis, freeze-dried broccoli powder and air-dried broccoli 
sprout powder was hydrolyzed by mixing 1:15 (w/v) with water and incubated without 
exogenous myrosinase at room temperature in the dark for 24 hours. Broccoli sprout hydrolysate 
was diluted 1:4 before extraction). Benzylisothiocyanate (0.5 mg/mL) was added as internal 
standard and the sample extracted into dichloromethane (1:2) and measured by gas 
chromatographic analysis, as previously described (116). Sulforaphane content for broccoli and 
broccoli sprouts was 0.72μmol/g DW and 7.66μmol/g DW, respectively. 
 
Statistical Analysis: 
Data were analyzed using SAS statistical software (SAS Institute Inc., Cary, NC). Data 
were compared among treatments using one-way ANOVA with Fisher’s LSD post-hoc for 
multiple comparisons, and compared between treatment and control (AIN93G) by Student’s t-
test and the Mann-Whitney non-parametric test. Values are means ± SEM, p < 0.05 was 
considered significant.  
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Table 8. Experimental diets 
Group Treatment 
1 Blank Control (AIN93G diet) 
2 10% Broccoli 
3 5% Broccoli Sprouts 
4 Low Gymnasterkoreayne B (GKB), 250 µmol/kg 
5 High GKB, 500 µmol/kg 
6 Low Gymnaster Extract (GE), 250 mg/kg 
7 High GE, 500 mg/kg 
8 Negative Control (AIN93G) + AOM/DSS 
9 10% Broccoli + AOM/DSS 
10 5% Broccoli sprouts + AOM/DSS 
11 Low GKB, 250 µmol/kg + AOM/DSS 
12 High GKB, 500 µmol/kg + AOM/DSS 
13 Low GE, 250 mg/kg + AOM/DSS 
14 High GE, 500 mg/kg + AOM/DSS 
  
 
 
Figure 16. Experimental timeline 
-12 d 0 wk  1 15 wks2 11 6 
Treatment Diets 1 % DSS
AOM
blood 
urine
Blood
urine
 
 
5.3   Results  
We had expected to complete the study at week 20 and harvest samples.  However, 
tumors grew faster than we anticipated and we ended the study at week 15. Most mice looked 
healthy at all times as measured by the Disease Activity Index (DAI) scores and the weekly 
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comments from the veterinary technician. All mice showing adverse signs and thus necessitating 
a medical case report were those that received AOM/DSS (Table 9). Six medical cases were 
culled early due to unlikely recovery from severe inflammation (Table 10). By week 15, the DAI 
scores revealed that mice receiving the broccoli and high Gymnaster Extract (GE) diets 
experienced fewer symptoms associated with inflammation, from that seen in mice receiving 
AOM/DSS. Those receiving the high GE diet exhibited the least inflammation (Figure 17).  
 
 Body weight and food intake:  
Figure 18 shows food intake for the first 2 weeks of the study. Food intake dropped in all 
treatment groups after AOM administration (day 0), but recovered during (day 7-13) and was 
fully recovered by day 14, after DSS treatment. In mice receiving the herbal fraction (GE) and 
the isolated compound (GKB) but no carcinogen, there were no significant differences in food 
intake and body weight compared to control during the entire study.  In mice receiving the herbal 
fraction and compound and AOM/DSS there was also no significant impact on food intake or 
weight gain. Food intake was not significantly affected by dietary treatment of broccoli. Figure 
19 shows weekly body weights between treatment groups. Body weight did not differ between 
treatment groups until the final week, when weight of mice receiving AOM/DSS and the 
broccoli sprouts diet was significantly reduced compared to AOM-free mice receiving sprouts 
(Figure 20).  
 
 Effect of dietary and AOM/DSS treatments on colon length and liver weight: 
Typically, the colon is shortened in chronic inflammation (60). Mice receiving the 
standard AIN93G diet and AOM/DSS had significantly shorter colons (Figure 21). With the 
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exception of the high dose A164a diet (500µmol/kg diet), mice receiving the KIST herbal 
treatments did not experience significant shortening of the colon. The broccoli and broccoli 
sprouts diets were comparable in that mice receiving these diets did not exhibit significant signs 
of colon shortening. Changes in liver weight may indicate potential toxicity resulting from 
exposure to dietary components or other chemicals (117). Mice receiving the sprouts, low 
compound and low GKB diets along with AOM/DSS had a significant reduction in liver weight 
as compared to their AOM-free counterparts (Figure 22).   
 
Incidence and multiplicity of colon tumors: 
Colons were evaluated for total number of tumors (Table 11), including adenomas (AD), 
which are considered pre-cancerous and adenocarcinomas (ADC) which are cancerous (118). 
The average number of adenocarcinomas was significantly reduced by two dietary treatments: 
high fraction diet (Hi-GE) and the 10% broccoli diet. Both of these diets decreased malignant 
adenocarcinomas by 90% when compared to AOM/DSS alone. None of the other diets caused a 
significant decrease in the number of adenocarcinomas, compared to mice receiving AIN93G 
plus AOM/DSS. The average number of adenomas per mouse was not significantly decreased by 
any of the treatments. The high dose of GE and the broccoli diets proved to have the most 
substantial effect overall on reducing tumor multiplicity. 
 
Dietary treatment effects on proliferation and inflammation in normal and tumor tissue: 
Hyperproliferation of cells is a critical feature in the initiation and progression of colon 
cancer (119). Cell proliferation has been shown to increase in the DSS/AOM mouse model 
during and after administration of the carcinogen (120). Results from the immunostaining for 
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Proliferating Cell Nuclear Antigen appear in Table 12. Both the high GKB and high GE 
treatment diets (500 µmol/kg diet) significantly decreased cell proliferation in tumor tissue. 
Proliferation was not altered in normal tissue surrounding the tumor tissue in mice receiving the 
high GKB and high GE diets. Cell proliferation was significantly reduced in tumor tissue of mice 
treated with the 10% broccoli diet. The 5% sprouts diet caused a slight reduction, but this was 
not found to be different from the AIN93G group. Similar to the lack of effect the Gymnaster 
diets on cell proliferation in surrounding normal tissue, neither 10% broccoli nor 5% broccoli 
sprouts  impacted proliferation rates in normal tissue surrounding tumor tissue or tissue from 
mice receiving the AIN93G diet. Within treatment groups, proliferation in tumor and normal 
tissue was found to be significantly different, except in the high GKB treatment group.  
Epidemiological and clinical studies demonstrate that anti-inflammatory drugs, such as 
aspirin, are effective in reducing the progression of colon cancer. This efficacy is attributed to 
the inhibition of COX-2 (121). Several different COX-2 inhibitors have been shown to 
significantly suppress tumorigenesis in the DSS/AOM mouse model (122). In this study, we 
show a significant reduction in expression of COX-2 in tumor tissue from mice given either the 
high GKB or high GE diets (Table 13). There was no significant difference in COX-2 expression 
between treatment groups within normal tissue. Interestingly, in mice given the high GE diet, the 
expression of COX-2 within tumor tissue was found to be significantly reduced when compared 
to expression in normal tissue. Similar to the Gymnaster diets, broccoli and broccoli sprouts diets 
were found to reduce induction of inflammation significantly, measured as COX-2 expression, 
within tumor tissue when compared to tissue from mice on control, AIN93G diet. No significant 
differences in expression were found between dietary groups in normal tissue. COX-2 expression 
within tumor and normal tissue fields of broccoli dietary groups was not statistically different. 
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Interleukin 6 (IL-6) is expressed in response to inflammation and is thought to trigger 
COX-2 expression and resulting prostaglandin E2 synthesis, leading to promotion of tumor cell 
differentiation and growth (123-125). Tables 14 shows the results from the Enzyme-Linked 
ImmunoSorbent Assay for IL-6 carried out on serum collected at cull. The high GKB 
(500µmol/kg diet) and low GKB (250µmol/kg diet) diets slightly decreased IL-6 in the serum of 
AOM mice, but this decrease was not significant. However, the low GE (250µmol/kg diet) and 
high GE (500µmol/kg diet) diets significantly reduced serum IL-6 when compared to AIN93G in 
mice given AOM/DSS. There were no significant differences found in IL-6 levels between any 
dietary groups within the control (AOM-free) mice. Serum IL-6 levels in control and AOM/DSS-
treated mice were not found to differ for either the high GKB or low GKB diets. The 10% 
broccoli and 5% broccoli sprouts diets reduced levels of IL-6 in the serum of AOM treated mice. 
Surprisingly, among the control (no AOM/DSS) mice, serum levels of IL-6 in mice treated with 
broccoli and broccoli sprouts showed a significant increase when compared to mice given the 
AIN93G diet and no AOM/DSS. Levels of IL-6 were not statistically different between control 
and AOM/DSS-treated mice within broccoli and broccoli sprouts treated mice. 
 
Dietary effect on hepatic detoxification enzyme levels:  
Phase II enzyme induction can protect against cancer initiation by detoxifying reactive 
oxygen and nitrogen species and neutralizing electrophiles and radicals (126). In particular, 
induction of the phase II enzyme NAD(P)H:quinone reductase (NQO1) has been offered as a 
possible mechanism by which dietary bioactive components can suppress the initiation of colon 
cancer (127, 128). Figure 23 shows the effects of dietary treatments on NQO1 induction in the 
liver of control mice and AOM/DSS-treated mice. Interestingly, mice treated with AOM/DSS 
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plus the high GE diet significantly increased NQO1 activity over the control, AIN93G-fed mice. 
This correlates with the increases in NQO1 activity found by KIST scientists in their in vitro 
work using these same compounds (1).  No other notable differences were found in NQO1 
activity between dietary treatments. Figure 23b shows the effects of broccoli and broccoli sprouts 
on NQO1 enzyme induction in the liver. 10% broccoli had no significant effect on NQO1 
activity, however the 5% broccoli sprouts diet and AOM/DSS-treated mice had significantly 
higher NQO1 activity in liver tissue, when compared to livers from mice receiving the control 
AIN93G diet. 
The cytochrome P450 enzyme family plays a major role in drug and xenobiotic 
metabolism and is involved in carcinogen activation (91). Cytochrome P450 1A (CYP1A) is 
known to be induced by some dietary compounds, measured as an increase in EROD activity. 
Figure 24 shows the results of the EROD assay in mice receiving the dietary treatments. Mice 
treated with AOM/DSS and high GE had significantly higher EROD activity when compared to 
AOM/DSS-treated mice receiving the AIN93G diet. No other significant differences were found 
between treatment groups; however, for mice on most experimental diets, hepatic EROD activity 
was elevated when compared to livers of mice on the basal, AIN93G diet. Figure 24b shows 
EROD activity in livers of mice given broccoli or broccoli sprouts. Livers from mice not 
receiving AOM/DSS, but given 10% broccoli had significantly higher EROD activity when 
compared to livers from saline or AOM/DSS-treated mice receiving AIN93G. Hepatic EROD 
activity in mice fed broccoli sprouts was not statistically different from that of AIN93G-treated 
mice. 
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5.4   Discussion 
 
In this study the extract from Gymnaster koraiensis was found to have potential as a 
chemopreventative agent against inflammation-enhanced colon cancer. The high dose of GE, but 
not pure GKB, caused a significant 90% drop in ADC per mouse, with no change in AD per 
mouse, possibly indicating decreased progression from AD to ADC. Mice given the high GE diet 
in addition to AOM/DSS not only exhibited significantly reduced tumor multiplicity, but had 
significantly lower DAI scores, normalized colon length, and decreased colonic epithelial COX-
2, PCNA labeling and serum IL-6 levels in comparison to mice receiving AOM/DSS and the 
control diet. Significant reduction of ADC was not seen in mice receiving the low GE diet plus 
AOM/DSS; however, this diet was just as effective as the high GE diet at reducing inflammation 
measured by serum IL-6 levels, COX-2 and PCNA labeling indices. In contrast, whereas isolated 
GKB may also possess some anti-inflammatory effects as shown by decreased COX-2 and 
PCNA labeling, it was not as effective as the high GE diet at suppressing DAI scores or at 
maintaining colon length, and was less able to decrease tumor multiplicity compared to the GE.  
In an earlier study, NQO1 was seen to increase with GKB treatment of hepatocytes in 
culture and in livers of rats given GKB for 5 days [2]. Although there was no significant increase 
in NQO1 over control caused by GKB in the current study, it is possible that mice may adapt to 
chronic exposure to GKB, such that any change in NQO1 activity seen in the first week of the 
study would diminish by week 15. In contrast, GE caused a persistent induction of NQO1.  
Changes in detoxification enzymes, such as NQO1, frequently indicate lowered tumor incidence 
and multiplicity.  In this study, the persistent enhancement of NQO1 may be part of the reason 
that GE but not GKB significantly reduced tumor multiplicity in mice. 
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The xenobiotic response element (XRE) is involved in the transcriptional upregulation of 
CYP1A through the aryl hydrocarbon receptor pathway. The XRE is known to be upregulated in 
response to procarcinogens, such as polycyclic aromatic hydrocarbons and other environmental 
pollutants. GKB did not significantly induce EROD activity. This data is consistent with earlier 
findings in vitro, that the lack of the XRE, required for EROD induction, did not impact the 
effect of GKB [2]. However, GE caused an increase in EROD. These results indicate that GE 
may contain a variety of components capable of upregulating either phase I or phase II 
detoxification enzymes. This is similar to our chemoprevention studies using broccoli and 
broccoli sprouts as a dietary treatment, where sprouts only provide aliphatic isothiocyanates and 
induced NQO1, yet mature broccoli, known to provide a lower level of  isothiocyanates, but to 
also provide indole metabolites, only induced the phase I enzyme EROD.  
For this study, the dose of GE was normalized to the concentration of GKB. Yet the 
extract was a more effective anti-inflammatory and anti-tumor agent than purified GKB. Several 
compounds found in Gymnaster koraiensis are structurally related to GKB, all of which might 
add to the anti-cancer impact of the extract. Gymnaster koreayne A-F were isolated from GK and 
tested for cytotoxicity in the L1210 mouse leukemia cell line [24]. While not the most potent 
inducer of tumor cell death in those in vitro studies, GKB caused significant cytotoxicity (ED50 
value of 3.3µg/mL); ED50 values for other components, found in less quantity, ranged from 2.1 
to 9.6µg/mL [24]. Recently, several other compounds isolated from GK were tested for 
cytotoxicity in four different human tumor cell lines. Although purified GKB was not found to 
have a significant effect in that study, there were three other compounds which had a moderately 
cytotoxic effect in the cell lines tested, including a colon cancer cell line, HCT15 [1]. 
Interestingly all three of those preparations contained the flavonoid apigenin. Apigenin is anti-
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carcinogenic flavone which can be found in carrots, celery and cilantro. Apigenin has recently 
been shown to significantly reduce high multiplicity, aberrant crypt foci formation in AOM-
treated rats, decreasing proliferation and increasing apoptosis (1 mg/kg diet) [25]. However, 
apigenin is found in the ethyl acetate fraction of GK, whereas we treated mice with the hexane 
fraction, which is devoid of apigenin. The hexane fraction contains other minor components, 
including Gymnasterkoreaynes B, C, E, and 2,9,16-heptadecatrien-4,6-dyne-8-ol, one or more of 
which may synergize with GKB to provide the protection against tumorigenesis we saw from 
GE. As mentioned earlier, Gymnasterkoreaynes B, C and 2,9,16-heptadecatrien-4,6-dyne-8-ol 
have been found to provide substantial cytotoxicity against L1210 tumor cells with ED50 values 
ranging from 0.12-3.3 µg/mL (129, 130).  These data suggest that future studies should be 
directed toward a comparison of the whole herb with a combination of polyacetylenes and 
flavonoids found within the whole herb, Gymnaster koraiensis.  
The 10% broccoli diet was found to have potential as a chemopreventive agent against 
inflammation-enhanced colon cancer. The 10% broccoli diet, but not the 5% broccoli sprouts 
diet, caused a significant 90% drop in ADC per mouse, with no change in AD per mouse, 
possibly indicating decreased progression from AD to ADC. Mice given the 10% broccoli diet in 
addition to AOM/DSS not only exhibited significantly reduced tumor multiplicity, but had 
significantly lower DAI scores, normalized colon length and liver weight, and significantly 
reduced colonic epithelial COX-2, PCNA labeling and serum IL-6 levels in comparison to mice 
receiving AOM/DSS and the control diet. Similar to the situation between GE and GKB, the 5% 
broccoli sprouts diet possessed some anti-inflammatory effects as shown by reduced serum IL-6 
and COX-2, but it was not as effective at suppressing DAI scores or maintaining body weight 
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and liver weight and was less able to decrease tumor multiplicity compared to the 10% broccoli 
diet.  
Broccoli is a known inducer of EROD activity, while broccoli sprouts are known to 
induce NQO1 activity in the liver (131-135). In keeping with these known observations, there 
was no significant increase in NQO1 over control caused by 10% broccoli in the current study, 
while NQO1 activity was enhanced by broccoli sprouts. In contrast, no change over control was 
seen for EROD activity in broccoli sprouts treated mice; however, 10% broccoli treated mice had 
enhanced EROD activity in the liver over control mice. The role of CYP1A-dependent EROD 
induction in reduction of tumor incidence is controversial, with many scientists concerned that 
induction of CYP1A may enhance incidence of cancer, since many polycyclic carcinogens, such 
as dimethylbenzanthracene, are activated by CYP1A. This is not the case with azoxymethane, 
which is metabolized in the liver to its active carcinogenic form, methylazoxymethane, by 
Cytochrome P450 2E1 (136). Thus, enhanced EROD activity may be part of the reason broccoli 
was able to provide more protection against colon tumor advancement than broccoli sprouts in 
mice. 
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Table 9. Summary of Medical Cases 
ID Treatment Weight 
loss 
Stool 
formation 
Fecal bleeding Other 
50 AIN-93G 1-5% Moderate loose 
stool 
Moderate bleeding  
18  1-5% Mild loose stool Moderate to gross 
bleeding 
 
97 Broccoli 1-5% Normal Mild bleeding  
87  None   Mass on 
abdomen 
74 Sprouts 1-5% Normal Moderate bleeding  
41  5-10% Mild loose stool Moderate bleeding  
53  None Normal Moderate to gross 
bleeding 
 
15 Hi-GKB* None Normal Gross bleeding 
(recovered after 1 wk) 
 
69  5-10% Normal Moderate to gross 
bleeding 
 
28 Lo-GKB** 
 
None Normal Moderate bleeding  
16  None Normal Moderate to gross 
bleeding 
 
60  None Normal Mild bleeding  
42 Hi-GE
1 
None Normal Mild to moderate 
bleeding 
 
1  None Mild loose stool Moderate bleeding  
12 Lo-GE
2 
 
None Normal Mild bleeding  
7  None   Mass on 
abdomen 
44  1-5% Normal Gross bleeding 
(recovered after 1 wk) 
 
*Containing 500 umol/kg diet A164a 
**Containing 250 umol/kg diet A164a 
1
Containing 500 umol/kg diet DFR-11 
2
Containing 250 umol/kg diet DFR-11 
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Table 10. Mice culled early for medical causes 
 
ID Treatment Weight 
loss 
Stool 
formation 
Fecal 
bleeding 
Other 
63 AIN-93G 1-5% Moderate 
loose stool 
Mild-gross 
bleeding 
Prolapsed 
rectum 
29 Sprouts 5-10% Mild-moderate 
loose stool 
Gross 
bleeding 
Necrotic 
tissue/prolapsed 
rectum 
34 Hi-GKB 1-5% Mild loose 
stool 
Gross 
bleeding 
Necrotic tissue 
on rectum 
65 Lo-GKB 5-10% Mild-moderate 
loose stool 
Gross 
bleeding 
Dehydration, 
extreme 
lethargy 
13 Hi-GE 5-10% Mild-moderate 
loose stool 
Gross 
bleeding 
Prolapsed 
rectum 
11 Lo-GE 1-5% Moderate 
loose stool 
Moderate 
bleeding 
Ulcerated 
skin/prolapsed 
rectum 
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Figure 17. Comparison of Disease Activity Index (DAI) scores between AOM/DS-treatment 
groups during the week of sacrifice1 
 
A. Average DAI scores of mice receiving control or Korean herbal diets 
 
B. Average DAI scores of mice receiving control or broccoli diets 
 
1
 Mice receiving different diets but no AOM/DSS all had DAIs of zero (data not shown).  
Means ± SEM, p < 0.05 using Mann-Whitney test against the AIN-93G group 
*   Significantly different from AIN-93G (p < 0.07) 
** Significantly different from AIN-93G (p < 0.05)  
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Figure 18. Food intake during AOM/DSS treatment1 
 
A. Average food consumption of mice receiving control or Korean herbal diets 
 
B.  Average food consumption of mice receiving control or broccoli diets 
 
1
Food intake of mice was measured starting with the acclimation period and through AOM/DSS 
treatment.  
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Figure 19.  Increase in body weights of mice, reported weekly1 
 
A. Average weight of mice receiving control or Korean herbal diets (n=7) 
 
B. Average weights of mice receiving control or broccoli diets (n=7) 
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Figure 20.  Final body weight measured at cull1 
 
A. Final body weight of mice receiving control or Korean herbal diets (n=7) 
 
B. Final body weight of mice receiving control or broccoli diets (n=7) 
 
 
1
Filled bars = control, open bars = AOM/DSS 
Mean ± SEM, p < 0.05, one-way ANOVA, using Fisher’s LSD 
*Indicates significant difference between control and AOM treatments 
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Figure 21. Effect of dietary and AOM/DSS treatments on colon length1 
 
A. Colon length of mice receiving control or Korean herbal diets 
 
B. Colon length of mice receiving control or broccoli diets 
 
1
Colons were removed distal from the cecum to distal from the rectum, flushed with 1.15% KCl 
and measured. Filled bars = control, open bars = AOM/DSS.  Different letters indicate 
significant differences. Mean ± SEM, p < 0.05, one-way ANOVA, using Fisher’s LSD 
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Figure 22. Effect of dietary and AOM/DSS treatments on liver weight1 
 
A. Liver weight of mice receiving control or Korean herbal diets 
 
B. Liver weight of mice receiving control or broccoli diets 
 
1
Livers were perfused with ice-cold 1.15% KCl, removed and patted dry, then weighed. Filled 
bars = control, open bars = AOM/DSS. Mean ± SEM, p < 0.05, one-way ANOVA, using 
Fisher’s LSD. Different letters indicate significant differences  
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Table 11. Incidence & multiplicity of tumors in the colon of mice treated with AOM1 
A. Effect of Korean herbal diets on tumor number 
 
 
 
 
 
 
 
B. Effect of broccoli diets on tumor number 
  
Multiplicity (no. of tumors/mouse) 
 
Treatment  Total  ADC2 AD3 Total  
AIN-93G 1.71 ± 0.65 1.43 ± 0.66 0.29 ± 0.2 5/7 
Broccoli 0.71 ± 0.31 0.14 ± 0.15
*
 0.57 ± 0.22 4/7 
Sprouts 1.00 ± 0.41 0.57 ± 0.32 0.43 ± 0.22 4/7 
 
1
Lesions on colon tissue from mice were identified microscopically, preserved in 10% formalin and determined to be either 
adenocarcinomas or adenomas by histopathology. Mean ± SEM, p < 0.05 using kruskal-wallis non-parametric test 
2
ADC: Adenocarcinoma 
3
AD: Adenoma 
 
 
Multiplicity (no. of tumors/mouse) 
 
Treatment  Total  ADC2 AD3 Total  
AIN-93G 1.71 ± 0.65 1.43 ± 0.66 0.29 ± 0.2 5/7 
Hi-GKB 1.29 ± 0.81 0.57 ± 0.32 0.71 ± 0.61 3/7 
Lo-GKB 1.43 ± 0.32 0.86 ± 0.22 0.57 ± 0.22 6/7 
Hi-GE 0.71 ± 0.31 0.14 ± 0.15
*
 0.57 ± 0.22 4/7 
Lo-GE 1.57 ± 0.62 0.71 ± 0.31 0.86 ± 0.44 4/7 
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Table 12. Proliferating Cell Nuclear Antigen immunohistochemistry of the colon in AOM treated mice1 
A. Effect of Korean herbal diets on cell proliferation 
 
B. Effect of broccoli diets on cell proliferation 
 
 PCNA-labeling index (%) 
Treatment            AOM (tumor fields) AOM (normal fields) 
AIN-93G 82.3 ±0.03
a, 1
 57.0 ±0.04
a,2
 
Broccoli 70.2 ±0.03
b,1
 55.8 ±0.03
a,2
 
Sprouts 73.8 ±0.03
ab,1
 55.1 ±0.04
a, 2
 
 
1
Colon sections stained for Proliferating Cell Nuclear Antigen (PCNA) were used to detect % positively-stained nuclei. Tumor fields 
include hyperplasia within tissue, adenomas and adenocarcinomas. Normal fields include both distal and proximal sections within 
carcinogen treated mice. Mean + SEM, one-way ANOVA, p < 0.05 using Fisher’s LSD. Different letters indicate significant 
differences within the same column. Different numbers indicate significant differences within the same row 
 
 
 
 
    PCNA-labeling index (%) 
Treatment AOM (tumor fields) AOM (normal fields)  
AIN-93G 82.3 ±0.03
a, 1
 57.0 ±0.04
a,2
  
Hi-GKB 69.2±0.05
b,
 
1
 54.4±0.05
a,
 
1
  
Hi-GE 70.2±0.02
b,
 
1
 55.3±0.03
a,
 
2
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Table 13. Cyclooxygenase-2 immunohistochemistry of the colon in AOM treated mice1 
 
A. Effect of Korean herbal diets on COX-2 induction 
 
 COX-2 labeling index (%) 
Treatment AOM – Tumor Fields AOM – Normal Fields 
AIN93G 27.30 ± 2.42
a,1 
21.63 ± 1.92
a,1
 
Hi-GKB 20.48 ± 2.31
b,1
 24.46 ± 2.61
a,1
 
Hi-GE 15.68 ± 1.45
b,1
 23.05 ± 1.85
a,2
 
 
 
B. Effect of broccoli diets on COX-2 induction 
 
 COX-2 labeling index (%) 
Treatment AOM – Tumor Fields AOM – Normal Fields 
AIN93G 27.30 ± 2.42
a,1 
21.64 ± 1.92
a,1 
Broccoli 17.24 ± 3.20
b,1 
20.47 ± 1.28
a,1 
Sprouts 15.32 ± 1.28
b,1 
18.78 ± 2.12
a,1 
 
 
1
Colon sections stained for COX-2 were used to detect % positively-stained nuclei. Tumor fields include hyperplasia within tissue, 
adenomas and adenocarcinomas. Normal fields include both distal and proximal sections within carcinogen treated mice. Mean ± 
SEM, one-way ANOVA, n=7, p < 0.05 using Fisher’s LSD and Student’s T-test between normal and tumor fields. Different letters 
indicate significant differences within the same column. Different numbers indicate significant differences within the same row. 
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Table 14. Measurement of serum IL-6 by ELISA1 
 
A. Effect of Korean herbal diets on induction of interleukin-6 in the serum 
 
 
B. Effect of broccoli diets on induction of interleukin-6 in the serum 
 
 Serum IL-6 concentration (pg/mL) 
Treatment Control AOM/DSS 
AIN-93G 3.24 ± 0.99
b,1
  33.85 ± 5.00
a,2
  
10% Broccoli 7.56 ± 0.78
a,1
  15.91 ± 4.20
b,1
  
5% Sprouts  7.82 ± 0.52
a,1
  16.65 ± 6.29
b,1
  
 
1
Serum collected at the end of the study was assayed for IL6 by enzyme-linked immunosorbentassay (ELISA). Mean + SEM, n=7, 
one-way ANOVA, p < 0.05 using Fisher’s LSD and Student’s t-test between control and AOM/DSS. Different letters indicate 
significant differences within the same column. Different numbers indicate significant differences within the same row.  
 Serum IL-6 concentration (pg/mL) 
Treatment Control AOM/DSS 
AIN-93G 3.24 ± 0.99
a,1
 33.85 ± 5.00
a,2
 
Hi-GKB 5.83 ± 0.62
a,1
 24.59 ± 8.17
ab,1
 
Lo-GKB 4.48 ± 0.83
a,1
 25.47 ± 7.51
ab,1
 
Hi-GE 5.88 ± 0.90
a,1
 19.40 ± 3.21
b,2
 
Lo-GE 4.94 ± 0.27
a,1
 20.12 ± 2.94
b,2
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Figure 23. Induction of NAD(P)H-quinone oxidoreductase-1 (NQO1) activity1  
 
A. Effect of Korean herbal diets on QR enzyme induction in liver 
 
B. Effect of broccoli diets on QR enzyme induction in liver 
 
1
Activity of cytosolic NQO1 activity was measured in liver. Filled bars = control, open bars = 
AOM/DSS. Mean ± SEM, one-way ANOVA, n=7, p < 0.05 using Fisher’s LSD and Student’s T-
test. Different letters indicate significant differences between all bars.
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Figure 24. Induction of ethoxyresorufin-O-deethylase (EROD) activity1 
 
A. Effect of Korean herbal diets on EROD enzyme induction in liver microsomes 
 
B. Effect of broccoli diets on EROD enzyme induction in liver microsomes 
 
1
Activity of CYP1A by microsomal EROD enzyme induction was measured in the liver. Filled 
bars = control; open bars = AOM/DSS. Mean ± SEM, one-way ANOVA, n=7, p < 0.05 using 
Fisher’s LSD and Student’s T-test. Different letters indicate significant differences between all 
bars. 
*Indicates significant difference between filled and unfilled bars within the same treatment 
group. Data were normalized using log transformation. 
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Table 15. Standard AIN-93G diet composition 
Gymnaster Extract and Gymnasterkoreayne B were added to the soybean oil before mixing 
Formula (1 Kg diet) AIN-93G (g/Kg) 
Casein 200.0 
Celluose 50.0 
Corn Starch 397.486 
Maltodextrin 132.0 
Sucrose 100.0 
L-Cystine 3.0 
Mineral Mix  35.0 
Vitamin Mix 10.0 
Choline Bitartrate 2.5 
Soybean Oil 70 
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Table 16. Broccoli sprouts diet calculation 
 
Formula (1 Kg diet) AIN-93G (g/Kg) 5% Broccoli sprouts 
Sprouts -- 50.0 
Casein 200.0 176.64 
Celluose 50.0 31.64 
Corn Starch 397.486 397.5 
Maltodextrin 132.0 129.15 
Sucrose 100.0 97.84 
L-Cystine 3.0 3.0 
Mineral Mix  35.0 31.66 
Vitamin Mix 10.0 10.0 
Choline Bitartrate 2.5 2.5 
Soybean Oil 70 70 
 
 
Broccoli sprouts, raw 
(source: http://www.broccosprouts.com/health/nutricontent.htm) 
Component Value/100g fresh weight 
(DW=10.7g) 
50g dry weight * 
Water 89.29  
Energy 57.14 kcal  
Protein 5.0 23.63 (example: 5.0*50/10.7) 
Total fat 0  0 
Ash (total mineral) .71 3.33 
Carbohydrate (+fiber) 6.79 31.71 
Fiber (total dietary) 3.93 18.34 
Sugars (total) 1.07 5.0 
*These values were used to calculate 5% dry weight broccoli sprouts in the diet. 
 
Adjusted AIN-93G diet as follows: 
Subtract protein from casein 
Subtract total lipid from soybean oil 
Subtract ash from mineral mix 
Subtract starch portion of carbohydrate from corn starch 
Subtract dietary fiber from cellulose 
Subtract ratio of sugar from maltodextrin and sucrose (calculated below) 
Maltodextrin  132 2.85 (=5.00*132/232) 
Sucrose   100 2.16 (=5.00*100/232) 
Total sugar (sprouts) 232 5.00 
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CHAPTER 6 
CONCLUSION 
 
 Initial studies (chapters 2 and 3) showed that DSS-induced inflammation in mice is a 
good model to test potential plant bioactive compounds as anti-inflammatory agents. We also 
observed that rappini and broccoli can protect against DSS (1%) induced shortening of the colon 
in mice. Our question then became whether or not broccoli, or other plant bioactive compounds, 
could protect against inflammation-enhanced colon cancer in mice. 
The most important findings from this research are that broccoli and the GKB-rich 
extract from Gymnaster koraiensis (GE) are able to protect both against some aspects of 
inflammation and slow the progression of colitis associated colon cancer, and against chemical-
induced carcinogenesis of the colon. Further work is needed to determine if the reason for greater 
efficacy of the GKB-rich extract compared to purified GKB is due to an additional active 
component(s) or to improved bioavailability of GKB. Possibly the substantial positive effect of 
the high dose of the extract in slowing the progression of benign adenomas to malignant 
adenocarcinomas may be due in part to its ability to decrease inflammation.  
Broccoli sprouts are higher in sulforaphane (7.66μmol/g DW) than broccoli (0.72μmol/g 
DW); therefore we expected that broccoli sprouts would be the positive control to study the 
effect of sulforaphane from whole broccoli. Sulforaphane is a known inducer of apoptosis in 
human colon cancer cells (137). A recent study showed that sulforaphane induces autophagy in 
colon cancer cells and that by inhibition of autophagy, that the pro-apoptotic effect of 
sulforaphane is heightened (138). The clinical significance of this study is that specific cellular 
mechanisms can be targeted during cancer treatment. Specifically, autophagy inhibitors may be 
useful by increasing the effectiveness of chemopreventive treatments.   
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However, in this study, broccoli was significantly more effective than broccoli sprouts in 
preventing the development of colon tumors from benign to malignant. This suggests that 
broccoli may contain a more desirable profile of bioactive components than broccoli sprouts and 
that sulforaphane may not be the most important bioactive to protect against tumor formation in 
the colon. Further investigation is needed into the mechanisms by which broccoli and its 
bioactive components can protect against inflammation and colon cancer.  
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